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Hb   Haemoglobin 
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HR   hazard ratio 
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At present, the diagnosis of diabetes mellitus (DM) is based on the result from either 
of three tests; HbA1c, fasting plasma glucose (FPG) or 2-hour post glucose-load value 
following an oral glucose tolerance test (OGTT). Although DM is one of the major 
risk factors for peripheral arterial disease (PAD), undiagnosed DM is common in 
PAD patients. Also, epidemiological studies have shown that FPG, the OGTT and 
HbA1c largely classify different patients as having DM and pre-DM. 
Studies have reported a negative association of abdominal aortic aneurysms (AAA) 
with DM. However, inconsistent results regarding long-term survival in both AAA 
patient of normal and abnormal glucose status are reported.  
Aims and Methods 
This was a prospective cohort study of patients with advanced vascular disease. The 
vascular pathologies were carotid stenosis, iliac occlusive disease (IOD), infra-
inguinal occlusive disease and AAA. 
In patients of unknown glycaemic status, the aim was to evaluate the performance of 
HbA1c as a diagnostic test for DM when using the OGTT as the gold standard (Paper 
I) and to explore the association of HbA1c levels, FPG values and OGTT results with 
long-term survival (Paper III).  
In Paper II, data from 66 AAA patients was used to investigate the prevalence of DM 
and pre-DM. Further, to evaluate the association of glycaemic status assessed by 





The prevalence of newly diagnosed DM was 12% and that of pre-DM was 33% based 
on OGTT results. An HbA1c value of ≥ 48mmol/mol (6.5%) detected DM with 
45.5% sensitivity and 90% specificity. The total prevalence of DM and pre-DM was 
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higher based on HbA1c values than based on the OGTTs. AUC for the association 




The total prevalence of known and newly diagnosed DM in 66 AAA patients were 
23% based on OGTT results. The prevalence of newly diagnosed DM in 58 AAA 
patients of unknown glycaemic status at baseline was 12% by OGTT results. HbA1c 
values classified DM patients according to OGTT results with 43% sensitivity and 
90% specificity. The prevalence of pre-DM was 43% based on OGTT results and 
72% based on HbA1c values.  
 
In 5.9 years follow-up, all-cause mortality in AAA patients of unknown glycaemic 
status was 43%. HbA1c was a significant independent predictor for mortality in the 
DM category, adjusted Hazard Ratio (HR) 6.35, (95% CI 1.49-27.1); p=0.01.  
 
Paper III 
Nine-years all-cause mortality in vascular surgery patients of unknown glycaemic 
status was 40%. HbA1c was an independent predictor for mortality, adjusted HR 1.54, 
(95% CI 1.03 – 2.32); p=0.04. The OGTT was not a predictor of long-term mortality.  
 
Conclusion 
Vascular surgery patients have a high prevalence of undiagnosed DM and pre-DM.  
The OGTT and HbA1c largely identify different patient groups as having DM and 
pre-DM. The number of vascular surgery patients having DM and pre-DM is higher 
based on HbA1c values than based on OGTT measurements. 
In patients with advanced vascular disease and of unknown glycaemic status, HbA1c 
may be a useful marker to identify patients at high risk of a reduced survival rate 
following surgical treatment for PAD. 
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1. Introduction 
1.1 A Historical Perspective  
Atherosclerosis is a fundamental process of vascular ageing in humans1. 
Palaeontological studies have identified atherosclerosis in ancient mummies2, 3. In 
addition, paleo-genetic studies of Ötzi, the Tyrolean glacier-mummy (3300 BC), 
identified a genetic predisposition for cardiovascular diseases (CVD)3. Ageing and 
genetic predisposition are strong non-modifiable risk factors for atherosclerosis4, 5. 
Although atherosclerosis is part of the normal ageing in humans, some people 
develop symptomatic atherosclerotic disease whilst others do not. This may largely 
be explained by modifiable risk factors for atherosclerosis; diabetes mellitus (DM), 
hypertension, dyslipidemia, obesity and smoking6-9. 
The earliest reference to DM, reported as polyuria, was included in The Eber’s 
Papyrus dated 1550 BC10. Despite the ancient recognition of a polyuria-related 
disease, the first known description and attribution of DM was recorded in years 0-
100 AD10. At that time, DM was thought to be a disease of the kidneys. It was not 
until the 19th century that DM was defined as a pancreatic disease following the 
observation that removal of pancreas in dogs caused DM11. Thus, for millennia, DM 
persisted to be a rapidly evolving disease with a fatal outcome10, 11. 
The first milestone in the treatment of DM was the discovery of insulin in the 
1920’s12. After the implementation of insulin followed by Sulfonylurea and 
Metformin in the 1950’s and -60’s and thereafter the exponentially increasing 
treatment possibilities for DM13, DM patients have reached almost the same life 
expectancy as non-diabetic individuals. Hence, DM related micro- and macro-
vascular complications were introduced to clinicians as a new problem in patients 
with DM following improved treatment possibilities.  
Throughout the following decades, numerous studies that aimed to investigate and 
describe the increased risk of vascular complications in diabetes mellitus reported an 
increased risk for both micro- and macrovascular complications14-16.  
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Following studies showing that hyperglycaemia was associated with vascular 
complications, several intervention-studies aimed to evaluate if glucose lowering 
treatment aiming towards normalization of glucose levels would be protective of 
micro- and macrovascular complications17-23. 
In parallel with clinical studies on DM treatment, increasing evidence for prolonged 
anti-platelet therapy in vascular diseases emerged through the 1980’s and 1990’s and 
became a cornerstone in medical treatment of vascular disease24. Further, the link 
between atherosclerosis and dyslipidemia was established through intensive research 
during the 20th century followed by numerous intervention trials showing cholesterol 
lowering effect and prevention of vascular events and cardiovascular death25-27. 
The impact of multiple risk factors on cardiovascular related death in DM patients 
was reported in the early 1990’s28. The Diabetes Mellitus Insulin-glucose Infusion in 
Acute Myocardial Infarction (DIGAMI 1) study was performed in 1990-1993 in the 
early era of preventive medical treatment for vascular disease and reported a 
reduction in mortality for all treatment groups as well as markedly improved survival 
in the insulin infusion group29. The reduced mortality-rate following myocardial 
infarction in that study may be explained by the increased use of platelet inhibitors 
and antihypertensive medication. 
Recent intervention studies on the effect of Glucagon-like Peptide 1 (GLP-1) 
analogues and Sodium-Glucose Cotransporter 2 (SGLT-2) inhibitors have brought 
new advances and hopes in DM treatment by reducing cardiovascular events and 
cardiovascular related death in DM patients30-33. Anti-atherogenic effect due to 
reduced vascular inflammation is proposed as one possible mechanism for the benefit 
on cardiovascular outcome. However, caution should be made for the reported 
adverse effects, in particular the increased risk of ketoacidosis and amputations, 
related to treatment with sodium-glucose-transporter (SGLT-2) inhibitors30, 31. This 
emphasizes the need for personalized treatment in patients with DM and peripheral 
arterial disease (PAD).  
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1.2 Epidemiology 
Diabetes mellitus prevalence is increasing both nationally and globally causing an 
increased disease burden worldwide34. The World Health Organization (WHO) 
estimated the global overall prevalence of DM to be approximately 8.5% in 201435, 
which represents about a four-fold increase in DM prevalence over the past three 
decades. In a recent update, the Norwegian health authorities estimated that 
approximately 4.7% of the Norwegian population have DM, of which about 1/10 
have DM Type 1 and remaining DM Type 2 or other forms36.  
The prevalence of peripheral occlusive disease is reported to be 15-30%, increasing 
with advancing age and higher in at risk populations compared to in general 
populations37-39. Screening-studies have reported a prevalence of abdominal aortic 
aneurysms (AAA) of 4-9% in men and 0.5-2% in women40,41 whereas the prevalence 
of carotid stenosis is approximately 4%42. One third to half of PAD patients are 
asymptomatic and therefore untreated38, 43-45.  As a result, occlusive disease is 
frequently present before symptoms occur. Also, asymptomatic PAD patients carry a 
high risk for mortality and vascular events46. 
In contrast to the increase in DM prevalence, a decline in time trends for the 
prevalence of cardiovascular diseases and cardiovascular-related deaths is reported37, 
47-49. Reduction in smoking rates, improved surgical treatment, and increase in the 
rates of risk factor treatment are suggested explanatory factors. 
Also, a decline in AAA related mortality is seen in countries with falling smoking 
rates. Screening-programs, increased rates of elective AAA repair and improved 
outcome following AAA repair are suggested to be explanatory factors50.  
Life expectancy in Norway has increased with 22 months over the past decade. A 
high DM prevalence accompanied by an increase in life expectancy has resulted in a 
14.5% increase in disease burden related to DM36. In addition, DM and vascular 
diseases largely affect persons of working age, which may have implications on 
health services and health economy51.  
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1.3 DIABETES – Pathophysiology, Definition and Classification 
1.3.1 Pathophysiology – A Brief Overview 
DM occurs due to an imbalance in glucose homeostasis following insufficient insulin 
secretion and/or action52. It is characterized by hyperglycaemia and disturbances in 
protein-, lipid- and carbohydrate metabolism53. The understanding of DM 
pathophysiology has changed markedly since Sir Banting’s discovery of insulin and 
the then conception of an insulin-deficient state as the single pathology in DM. 
Research has contributed to an extended understanding of DM as a set of metabolic 
disorders with various genetic and environmental causes54. At present, eleven 
mediating pathways of hyperglycaemia are known, including the influence of 
numerous hormones and their interactions with target tissues (Fig. 1)54. 
 
Reduced beta cell mass and function leading to defective insulin secretion is the 
central element in DM pathophysiology (Fig. 1, Step 1). Insulin resistance in muscle, 
liver and adipose tissue is a main contributor to beta-cell dysfunction (Fig. 1, step 4-
6). Additional contributors are altered gut microbiota and low-grade systemic 
inflammation (Fig. 1, Steps 8 and 9). Also, through impaired appetite regulation, 
cerebral insulin resistance and inflammation-induced neuronal damage has been 
suggested as pathophysiological mechanisms for hyperglycaemia55, 56 (Fig. 1, Step 7).  
 
Consequences of beta-cell dysfunction are depicted in Steps 2, 3, 10 and 11 in Fig. 
154. Increased basal glucagon production results in increased basal hepatic glucose 
production56. Reduced incretin effect and reduced amylin levels leads to postprandial 
hyperglycaemia whereas an upregulation of SGLT-2 in the kidneys contributes by 
increased renal reabsorption of glucose. The net effect is accelerated fasting- and 
postprandial hyperglycaemia54. The action of toxic metabolites from increased 
glucose and fatty acid utilization results in reduced beta-cell mass and function, as 
well as the development of DM related micro-and macrovascular complications. The 
development of DM is seen as a continuum from low risk to overt disease53. Thus, 
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elevated glucose levels may be present years before DM diagnosis, which implies 




Fig. 1. A. Eleven currently known mediating pathways of hyperglycaemia. B. Current targeted therapies 
for each of the current mediating pathways of hyperglycemia. ©2016 by the American Diabetes 
Association ®. Diabetes Care 2016 Feb; 39(2): 179-18. Reprinted with permission from the American 
Diabetes Association ®. 
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1.3.2 Definition of Diabetes and Intermediate Hyperglycaemia 
The definition of DM and intermediate hyperglycaemia (pre-DM)57 is based on either 
glycosylated haemoglobin (HbA1c) levels, fasting plasma glucose (FPG) results or a 
2-hour post glucose load value following an oral glucose tolerance test (OGTT)53, 58.  
 
Table 1. WHO criteria for the diagnosis of diabetes and intermediate 
hyperglycaemia. 
Diagnostic criterion* Diabetes mellitus Intermediate 
hyperglycaemia 
HbA1c** ≥ 48 mmol/mol (6.5%) 42-47 mmol/mol (6.0-6.4%) 
Fasting plasma glucose ≥ 7.0 mmol/L 6.1-6.9 mmol/L 
2-h post glucose load value ≥ 11.1 mmol/L 7.8-11.0 mmol/l 
*A confirmative test is required if the tests are used for DM screening.                       
** HbA1c should be measured using a certified method referenced to the DCCT trial.  
Table 1 is reprinted with permission from WHO (© World Health Organization 2006. All rights 
reserved).  
 
The American Diabetes Association (ADA) uses an HbA1c range of 5.7-6.4%, a FPG-
range of 5.6-6.9 mmol/L and a 2-h post glucose load value of 7.8-11.0 mmol/L to 
define persons at high risk of developing DM57.  
Current WHO guidelines recommend HbA1c as the preferred diagnostic test for DM. 
Also, annual screening for DM in high-risk individuals by measuring HbA1c is 
recommended58. In a recent update on classification and diagnosis of DM, the 
American Diabetes Association equates HbA1c, FPG and the OGTT as diagnostic 




1.3.3 DM Classification 
DM is classified as DM Type 1, DM Type 2, gestational DM and specific types of 
DM due to other causes. The latter category includes the monogenic types of 
Maturity onset diabetes in the young (MODY), DM due to pancreatic diseases and 
DM due to medication or chemicals59.                                                                                                                  
DM Type 2 accounts for approximately 90% of all DM cases. Although DM is 
classified into distinct categories, the pathophysiology of DM is complex, and a 
phenotype based overlap between categories are seen60. Latent autoimmune diabetes 
of adult (LADA) is a form of autoimmune DM, classified as DM Type 1, and 
characterized by slow progression of beta-cell failure and a Type 2 diabetic 
phenotype61. Also, transient autoantibodies in patients with DM Type 2 have been 
described in a Norwegian population62. 
In a 2016 review, Leslie et al emphasized the need for a more precise characterization 
of DM patients to direct diagnostics and treatment towards precision medicine60. 
Recently, Ahlquist et al suggested a new subgrouping of DM patients based on 
parameters for the evaluation of beta-cell function and insulin resistance, the presence 
or absence of autoantibodies, age and BMI63. The subgrouping is proposed to provide 
information on the severity of DM and the risk for microvascular complications. 
However, the suggested subgrouping needs to be validated in further studies before 




1.4 Biomarkers of Glucose Metabolism 
Although the first method to detect blood glucose was developed by the Norwegian 
Ivar Bang64 in the early 20th century, it was not until the 1950’s that blood glucose 
measurements became available in clinical medicine65. Following the observation of a 
post-meal pathological elevated blood glucose level in several individuals, the OGTT 
was developed as a diagnostic test for DM during the 1960’s66. Studies on blood 
glucose distribution following an OGTT in Pima Indians led to standardization of the 
test. 
Fasting and non-fasting blood glucose levels and the OGTT are standardized and at 
present widely used as diagnostic tests for DM. Also, blood glucose measurements 
play a major role in monitoring DM treatment53. 
Fasting Plasma Glucose and The Oral Glucose Tolerance Test 
Venous plasma glucose is measured after eight hours overnight fasting. Following 
oral ingestion of 75g glucose, plasma glucose is measured two hours post glucose-
load for the OGTT. To prevent lowering of glucose by red blood cells, it is 
recommended that blood samples are centrifuged immediately to separate plasma, or 
drawn in tubes containing glycolytic inhibitors until centrifuged53.  
The diagnostic cut-off values of FPG and the OGTT for DM diagnosis are selected 
based on the threshold for increased risk of microvascular complications i.e. 
retinopathy and nephropathy16, 53. 
Limitations for the use of FPG and the OGTT as diagnostic tools for DM 
 
Glucose measurements show large biological variation, analytical variation, pre-
analytic instability, and they are affected by stress-related changes in blood glucose 
levels67. To be added, the OGTT is considered time consuming, relatively labour-
intensive, the reproducibility of the test is low and overnight fasting is required53, 68. 
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HbA1c    
                                                                                                                                                             
HbA1c is formed by the Maillard reaction, a non-
enzymatic binding of a glucose molecule to the N-
terminal end of the haemoglobin molecule (Fig. 2)69. 
HbA1c reflects the average blood glucose over the past 
8-10 weeks as established through the A1C-derived 
Average Glucose (ADAG) study (Fig. 2)70.                                                               
Compared to plasma glucose, HbA1c has better pre-
analytic stability, less inter-day variability, is less 
influenced by stress, and is measured irrespective of 
fasting57, 58, 71, 72. Clinicians have used HbA1c as a 
guidance-tool for DM treatment since the 1980’s73. The 
use of HbA1c in clinical practice is based on the 
association of HbA1c with retinopathy, DM development 
in observational studies71, 74, 75 and the prevention of 
microvascular complications by lowering HbA1c level 
in patients with established DM14, 17, 76. HbA1c was 
implemented as a diagnostic method for DM following 
the standardization of the HbA1c assay according to a National Glycohaemoglobin 
Standardization Program (NGSP)-certified method referenced to the Diabetes Control 
and Complication Trial (DCCT)77. 
Limitations for the use of HbA1c as a Diagnostic Marker for DM 
HbA1c measurements and results may be affected by conditions with altered 
erythropoiesis, erythrocyte destruction, altered glycation, variants of haemoglobin, 
and assay-interfering factors such as hyperbilirubinemia, hypertriglyceridemia and 
uremia78. Research has shown HbA1c values to be higher with advancing age and 
affected by ethnicity71, 79. Also, HbA1c is a poor discriminator for different categories 
of glucose dysregulation since it does not provide information about fasting glucose 
levels or glycaemic variability assessed by postprandial glucose levels.  
Fig. 2. The HbA1c molecule and the linear 
relationship between HbA1c and the 
glucose levels. The illustration is made 
available by written permission of The 
Regents of the University of California.    
All rights reserved. 
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1.5 PERIPHERAL ARTERIAL DISEASE                                    
– Pathophysiology, Definition and Classification 
1.5.1 Pathophysiology with a Hyperglycaemic Focus 
Atherosclerosis is the underlying pathological process in arterial diseases and refers 
to a chronic inflammatory process linked to endothelial dysfunction80, 81. Alterations 
in the interaction between the endothelium, the hemodynamics of arterial flow and 
blood composition initiate and facilitate atherosclerosis by inducing endothelial 
dysfunction80. DM affects all those interactions, and the risk of arterial disease in DM 
patients is related to the duration of DM and the presence of neuropathy7. 
DM leads to dyslipidemia and promotes atherosclerosis by inducing endothelial 
dysfunction due to hyperglycaemia, dyslipidemia and insulin resistance82,83. Also, 
DM is described to be a hyper-coagulable state due to enhanced platelet aggregation, 
increased production of tissue factor and coagulation factors, and decreased levels of 
antithrombotic factors7. 
During the last two decades, major research has focused on the role of endothelial 
dysfunction and inflammation in the development of atherosclerosis. Hyperglycaemia 
promotes non-enzymatic glycation of lipoproteins which affects vascular smooth 
muscle cell migration and apoptosis, a process of major interest for atherogenesis80.  
Glucose transporters are required for the glucose to enter the cells. Endothelial cells 
mostly express insulin-independent glucose transporters on their surface84. Hence, 
increased plasma glucose level will cause an increase in intracellular glucose 
concentration. Intracellular hyperglycaemia leads to mitochondrial overproduction of 
reactive oxygen species (ROS) and activation of four alternative pathways of glucose 
utilization; 1) increased polyol pathway flux, 2) activation of protein kinase C, 3) 
increased hexosamine pathway flux and 4) formation of advanced glycation end 
products (AGE)85. Together, these pathways promote atherogenesis by decreasing 
nitric oxide within endothelial cells, by activating several proinflammatory signals, 
by increasing vascular tone and vascular smooth muscle cell growth, and by 
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promoting thrombosis due to platelet activation and increased production of 
prothrombotic factors83.  
Hyperglycaemia and insulin resistance lead to the release of free fatty acids (FFA) 
from adipocytes. Increased mitochondrial oxidation of FFA in endothelial cells 
occurs following the increased level of FFA. This leads to mitochondrial ROS 
overproduction which in turn activate the four alternative pathways as described for 
hyperglycaemia with subsequent activation of proinflammatory signals85.  
The net effect of the above-mentioned pathological processes is accelerated 
atherosclerosis. 
1.5.2 Classification and Definition of Peripheral Arterial Disease 
Arterial disease is the clinical manifestation of atherosclerosis6. Peripheral arterial 
disease refers to non-coronary and extra-cranial vascular disease86, 87. The 
classification of peripheral arterial disease is based on anatomical localization and 
symptoms/clinical severity87.  
Classification Based on Anatomical Localization 
According to current guidelines, peripheral arterial diseases are classified as carotid 
stenosis, abdominal aortic aneurysmal disease and/or peripheral occlusive disease. 
Peripheral occlusive disease includes renal arterial disease, mesenteric arterial 
disease, inguinal occlusive disease, and infrainguinal occlusive disease86, 87. In the 
2017 European Society of Cardiology (ESC) guidelines, peripheral occlusive disease 
is named lower extremity arterial disease (LEAD)86. 
Schemes for anatomical classification of lower extremity occlusive disease are 
published by The Trans-Atlantic Inter-Society Consensus (TASC II) joint guidelines 
for the management of PAD4. Classification by TASC II is suggested to be used as 
guidance schemes for the choice of surgical treatment. Since multiple lesions often 
are present in advanced peripheral occlusive disease, a limitation of TASC II 
classification is the focus on individual lesions.    
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Symptom-based Classification of PAD 
Several systems for the symptom-based classification of PAD have been compiled88. 
According to the 2016 Updated Guidelines of the Society for Vascular Surgery, 
Rutherford classification system for grading the severity of PAD is the recommended 
system to be used89. That classification is based on clinical description and objective 
measures of arterial circulation. 
Also, a standardized grading-system for patient comorbidities is included in the 
current PAD guidelines89. The system is based on categorical grading of 
comorbidities and risk-factors such as diabetes, renal status, tobacco use, 
hyperlipidemia, hypertension, cardiac status, pulmonary status and functional status. 
Definition of Carotid Stenosis and AAA 
The diagnosis of carotid stenosis and AAA is based on ultrasonic measurements of 
the arterial occlusion or the aneurysmal expansion. AAA is defined as an aortic 
diameter >30mm87. Timing of surgical intervention is based on clinical presentation 
and the severity of stenosis or aneurysmal expansion89-91. 
Definition of Peripheral Occlusive Disease 
An Ankel-Brachial-Index (ABI) of ≤0.90 at rest and/or post-exercise is recommended 
as the first test to be used for screening and diagnosis of peripheral occlusive 
disease86, 92. Due to media sclerosis, patients with DM and patients at high age may 
have non-compressible arteries and thereby a falsely high ABI. Toe-pressure 




1.6 Arterial Disease and DM – Double Trouble   
Although DM is one of the major risk factors for PAD, undiagnosed dysglycaemia is 
common in patients with peripheral arterial disease93, 94, 45, 87. DM prevalence in 
patients with PAD is four times higher than in general populations at corresponding 
age groups93, 95-97. The increased risk for PAD in persons with DM is independent of 
other risk factors and related to the duration of DM44, 98. 
A major challenge in clinical handling of DM is the gradual onset and delayed 
diagnosis. Approximately 1/3 of patients with Type 2 DM are undiagnosed and 
therefore untreated and at high risk of complications and increased disease burden97, 
99-101. To facilitate early DM diagnosis, HbA1c was implemented as an additional 
diagnostic tool for DM 58, 71, 102. However, epidemiological studies have shown that 
FPG, the OGTT and HbA1c largely classify different patients as having DM and pre-
DM103-107.   
When using FPG and 2-h post glucose load values as criteria for the DM diagnosis, a 
negative association of abdominal aortic aneurysms (AAA) with DM was shown108-
110. However, studies that aimed to compare long-term survival in AAA patients with 
and without DM defined by an OGTT have reported inconsistent results110, 111. 
Patients with PAD have high mortality in both a short-term and a long-term 
perspective112, 113. A two-fold excess risk of mortality in patients with PAD and DM 
is reported44. Also, patients with PAD are likely to have concomitant coronary artery 
disease, cerebrovascular disease and impaired renal function114, 115. The presence of 
poly-vascular disease is linked to a worse long-term outcome116. The combination of 
poly-vascular disease and DM further enhances that risk117.  
Also, persons with DM have more often advanced occlusive disease, especially 
below the knee, compared with non-diabetic persons44. Hence, patients with arterial 
disease and DM run a five- to ten times higher risk for major amputation and a two-
fold higher risk of mortality in a four-year perspective than patients with arterial 
disease only4, 44.   
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The main contributor of fatal health loss (death and years of life lost) in DM patients 
and in patients with PAD is coronary artery disease44, 113, 118. DM implies a double 
CVD risk on average119.  
Together with hyperglycaemia, additional modifiable risk factors such as 
hypertension, hyperlipidemia, high BMI and smoking are main contributors to the 
disease burden related to DM and vascular diseases51, 120, 121. Increasing risk for PAD 
for each additional risk factor is reported122. Hence, the risk of DM-related 
complications is not restricted to hyperglycaemia alone. Numerous studies on DM 
patients have shown that blood-pressure control, lipid lowering treatment and 
smoking cessation trump glucose-lowering treatment for the prevention of CVD 
events123, 124.  
Current guidelines on management of DM and of PAD focus on multi-target therapy 
aiming towards risk factor reduction in addition to glucose lowering treatment59, 86, 87. 
In addition, differences in cardio metabolic risk in persons with DM type 2 are related 
to the diagnostic criterion used for the diagnosis of DM125. This emphasises the 
heterogeneity of DM and the need for a systematically risk-mapping of patients in 
order to be able to provide tailored treatment.  
In summary, extensive research has proven DM as a major risk factor for the 
development of vascular diseases. DM is also an additional contributor to increased 
disease burden in patients with PAD. For a complete risk assessment, PAD patients 
need to be tested for DM. At present, three different diagnostic parameters for DM 
are available. In this research project, the aim was to validate HbA1c against FPG and 
2-hour post-glucose load measurements for DM diagnosis in PAD patients. Further, 
information on long-term outcome following DM testing is required to evaluate the 
importance of a pathological test result. Therefore, based on HbA1c levels, FPG 
values and 2-hour post-glucose load measurements, this study aimed to investigate 
the association of pathological test results with long-term mortality in patients with 
advanced PAD.  
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2. Aims of the Study 
The overall aims in this project: 
 1. Evaluate the performance of HbA1c as a diagnostic test for DM in vascular surgery 
patients with unknown glycaemic status. 
2. Determine the ability of HbA1c, FPG and the oral glucose tolerance test (OGTT) to 
predict all-cause mortality during long-term follow-up. 
 
Specific Aims: 
Paper 1 To validate HbA1c as a method to diagnose DM in vascular surgery 
patients when using the OGTT as the diagnostic gold standard for DM.  
Paper 2 To investigate the prevalence of dysglycaemia in patients with 
abdominal aortic aneurysm and to evaluate mortality with respect to 
glycaemic status assessed by HbA1c and OGTT measurements.  
Paper 3 To evaluate HbA1c and the OGTT as predictors for long-term mortality 
in vascular surgery patients with unknown glycaemic status. 
 
Throughout this thesis, the term OGTT refers to the measurements of both FPG and 
2-hour post glucose load values. The term PAD includes carotid stenosis, iliac 
occlusive disease (IOD), infrainguinal occlusive disease and abdominal aortic 





3. Materials and Methods 
3.1 Study Population 
This research project was a prospective cohort study of vascular surgery patients with 
advanced vascular disease. The vascular pathologies were carotid stenosis, iliac 
occlusive disease (IOD), infrainguinal occlusive disease and abdominal aortic 
aneurysmal disease (AAA). 
Between October 2006 and September 2007, 465 patients admitted to the vascular 
surgery unit at Haukeland University Hospital, Bergen, Norway for elective surgery 
or contrast angiography, were invited to participate in the study. Of those, 66 (14%) 
declined to perform an OGTT and 21 (5%) died before deciding whether to 
participate. In addition, 33 (7%) patients did not have an OGTT performed due to 
logistic reasons and three patients had missing HbA1c values. Sixty-seven (14%) 
patients had known DM. 
All vascular surgery patients admitted to Haukeland University Hospital, Bergen, 
Norway, for treatment are included in the Norwegian Cardiovascular Disease 
Registry (NORKAR), governed by The Norwegian Institute of Public Health.  
The study cohort in Paper I and Paper III  
Patients having known DM at baseline, arterial disease of other causes than 
atherosclerosis and missing HbA1c or OGTT results were excluded.  
The study-cohort in Paper I included 275 vascular surgery patients of unknown 
glycaemic status, two of which with non-atherosclerotic disease. Those two patients 
were excluded in Paper III. Hence, in Paper III, data from 273 patients were used.  
The study cohort in Paper II  
Data from 66 AAA patients selected from the total cohort of vascular surgery patients 
was used. Patients with other vascular pathologies than AAA were excluded. Seven 
patients had known DM. One patient had missing HbA1c result. OGTT and HbA1c 
results from 58 AAA patients of unknown glycaemic status were included for the 
mortality analyses.  
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3.2 Baseline Data  
Relevant covariates at baseline were retrieved from the patients’ medical records and 
from data collected at the inclusion in the study. Information about the obtained 
patient characteristics at baseline is described in the respective papers.   
Characterization of the vascular pathologies were based on findings from duplex 
ultrasound imaging, computed tomography angiography (CTA) with injection of 
iodinated contrast and, if indicated, contrast angiography. Trained ultrasound 
technicians at the vascular unit performed the duplex ultrasound imaging. The CTAs 
were obtained by radiologic technologists. Specialists in interventional radiology 
performed the contrast angiographies. All cases, with accompanying images, were 
evaluated by specialists in vascular surgery and interventional radiology in joint 
vascular meetings.  
Based on the conclusions from the vascular meetings, patients in this research project 
were initially classified according to the relevant vascular pathology at inclusion.  
For the mortality analyses in Paper III, the candidate performed a re-categorization of 
patients with iliac occlusive disease and infra-inguinal occlusive disease based on a 
re-evaluation of angiogram descriptions. In cases of a multiple level disease, the 
patients were classified according to the distal findings.       
3.3 Diagnostic Tests 
Glucose levels of the OGTTs and HbA1c values were measured at baseline. Paper I 
holds a detailed description of diagnostic tests and laboratory methods.  
Oral Glucose Tolerance Tests (OGTTs) 
The OGTTs were performed by oral administration of 75g anhydrous glucose 
dissolved in water following a minimum of eight hours overnight fasting126. Plasma 
glucose was measured in a fasting state and again two hours after the ingestion of 
glucose. No dietary restrictions were given prior to the pre-test fasting.  
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In 78% of the cases, the OGTTs were performed at Haukeland University Hospital, 
Bergen, Norway, by a designated laboratory technician. In 61 patients (22%), the 
OGTT was performed at their respective General Practitioner’s (GP’s) offices due to 
logistic reasons. Of the OGTTs performed at the GP’s offices, 17 (28%) were 
analysed at Haukeland University Hospital and 27 (44%) were analysed immediately 
in capillary whole blood at the respective GP’s offices. Finally, plasma glucose for 17 
(28%) of the OGTTs performed at the GP’s offices were analysed at other regional 
hospitals. 
Venous whole blood, drawn in containers with glycolytic inhibitors (citrate and 
fluoride) and centrifuged within one hour from venous sampling to separate plasma, 
was used for the OGTT glucose measurements performed at Haukeland University 
Hospital. The pre analytical handling of the blood samples for the OGTTs performed 
at other regional hospitals was not known. 
The OGTT plasma glucose levels were analysed using the available resources at the 
different hospital laboratories.   
In 84% of the OGTTs, the glucose measurements were performed at Haukeland 
University Hospital by using the hexokinase assay on Roche Modular P (Roche 
Diagnostics, Indianapolis, U.S.A.).  
Glucose measurements for the remaining 16% of the OGTTs were performed by 
using the following equipment: Ortho-Clinical Diagnostics Vitros 950 Chemistry 
Analyzer (Ortho-Clinical Diagnostics, Rochester, New York, U.S.A.), Architect ci 
8200 Integrated System (Abbott Core Laboratories, Abbott Park, Illionis, U.S.A), 
Architect c 8000 Clinical Chemistry Analyzer (Abbott Core Laboratories), and Roche 
Hitachi 911 (Roche Diagnostics). 
At the GP’s offices, the following resources were used for analysis: HemoCue 
Glucose 201+ System (Wilburn Medical Inc, Kernersville, U.S.A.), HemoCue AB B 
Glucose Photometer (HemoCue Ltd. Ängelholm, Sweden) and Roche Reflotron Plus 




HbA1c values were measured on all participants through a single blood sample. In 
98% of the cases, HbA1c was analysed in the Department of Laboratory Medicine and 
Pathology, Haukeland University Hospital, Bergen, Norway, using HPLC Variant II 
Hemoglobin testing system (Bio-Rad Laboratories, Munich, Germany). The method 
correlates to the DCCT reference study and is traceable to the International 
Federation of Clinical Chemistry and Laboratory Medicine reference method. 
Four patients were tested at their GP’s office, and three patients at other regional 
hospitals. HbA1c values were then analysed using the following resources: HPLC 
Variant II Hemoglobin testing system (Bio-Rad Laboratories, Munich, Germany), 
DCA 2000 (Siemens/Bayer Diagnostics Europe, Dublin, Ireland), DCA Vantage 
Analyzer (Siemens Healthcare Diagnostics Inc., Tarrytown, New York, U.S.A), 
Roche Hitachi 912 (Roche Diagnostics), D-10 Hemoglobin Testing System (Bio-Rad 
Laboratories), NycoCard Reader Axis-Shield HbA1c assay (Abbott Laboratories) and 
Architect ci 8200 Integrated System (Abbott Core Laboratory).  
 
External Quality Assessment of the Laboratory Methods 
All performing laboratories in this research project participated in external quality 
assessment programs recommended or performed by the Norwegian Quality 
Improvement of Laboratory Examinations (Noklus).  
The range of Coefficient of Variation (CV) of the methods used for glucose 
measurements at the different hospital laboratories were 1.8% -3.0%. The results 
from external quality assessment of the equipment used for glucose measurements at 
the GP’s offices were referred to as accepted or not accepted. All reported values 
were accepted.  
The CVs of the methods used for HbA1c analyses were 0.8%-2.6% at HbA1c level 
5.4%-9.8%. Two blood samples were analysed on DCA 2000. CV of the DCA 2000 
was 4.2%-5.2% at an HbA1c level of 5.0%. All methods used for HbA1c analyses 
correlates to the Diabetes Control and Complication Trial reference study. 
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Classification of glycaemic status 
Based on the FPG levels, 2-hour post glucose load values and HbA1c results, the 
patients were categorized as having normoglycaemia, intermediate hyperglycaemia 
(pre-DM) and DM according to ADA and WHO criteria53, 57.  
3.4 Endpoints and Follow-up 
Main outcome was death of all causes. Information about deaths was obtained from 
the patients’ medical journals, which are linked to the Norwegian civil registry. 
Specific causes of death were not registered.  
Study participants were followed from the date of surgical intervention either to the 
date of death or to the date of study closure. Follow-up of the AAA patients presented 
in Paper II was closed on the 11th of August 2014. For the patients included in Paper 
III, the date of study closure was the 30th of August 2016. All study participants 
attended the outpatient program at the Department of Vascular Surgery at Haukeland 
University Hospital. 
3.5 Statistical Analysis  
Statistical analyses were performed in SAS, R, and Stata (Windows) and in SPSS 
Statistics 24 (IBM). Data were presented as mean ±standard error for continuous data, 
and as absolute count with percentage for categorical data.  The Chi-square test was 
used to explore associations between categorical variables. Associations between 
continuous data were analysed using independent samples T-test. Inspection of 
histograms was used for determination of skewness and kurtosis in order to evaluate 
normal distribution of the variables included for analysis. Outliers, defined as diabetic 
extreme values of OGTT and HbA1c measurements, were modified by changing their 
value to a less extreme value.   
The association between OGTT values (FPG and 2-h post glucose load values) and 
HbA1c values was examined by using segmented regression analysis. The 
performance of HbA1c, when using the OGTT as the gold standard, was evaluated by 
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inspection of receiver operating characteristic (ROC) curves and calculations of area 
under the curve (AUC) (Paper I).       
Cox regression models were used to estimate all-cause mortality hazard ratio with 
95% confidence intervals (CIs) for HbA1c, FPG and 2-h post glucose load results 
(Paper II and Paper III). Three adjustment models were constructed to evaluate the 
impact of possible confounding. Selection of covariates in the models was based on 
known risk factors associated with DM and PAD and established medical treatment 
for PAD. The proportional-hazards assumption was fulfilled for all variables in the 
final regression models. Survival was pictured using Kaplan Meyer Survival Curves. 
3.6 Ethical Aspects 
The research was carried out in accordance with the Declaration of Helsinki and 
principles of Good Clinical Practice. The research protocol was approved by the 
Regional Committee for Medical Research Ethics (REK vest 14109). Informed 
written consent was obtained from all participants.  
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4. Summary of Results 
A detailed presentation of results with accompanying figures is available in the 
respective papers. 
4.1 Paper I - Validation of HbA1c as a method to diagnose DM 
and intermediate hyperglycaemia in vascular surgery patients 
when using OGTT as the gold standard. 
In the 275 participating vascular surgery patients of unknown glycaemic status, 
glucose levels of the OGTTs and HbA1c values were measured at baseline. The 
patients were categorized according to WHO and ADA definition of DM and 
intermediate hyperglycaemia. The performance of HbA1c was evaluated by AUC 
calculations using the OGTT as the gold standard. 
Based on OGTT results, DM prevalence was 12% and the prevalence of intermediate 
hyperglycaemia was 33%.  An HbA1c value of ≥48 mmol/mol (6.5%) detected DM 
with 45.5% sensitivity and 90% specificity. According to HbA1c results, the 
prevalence of intermediate hyperglycaemia was 70%. The total prevalence of DM 
and intermediate hyperglycaemia was 85% based on HbA1c values and 45% based on 
the OGTTs. AUC for the association between HbA1c and the OGTT as diagnostic 
parameters for DM was 0.73 (95% CI 0.63, 0.84).  
Patients diagnosed with intermediate hyperglycaemia by OGTT results had the 
highest prevalence of reduced renal function and were more likely to be former or 
current smokers when compared to DM patients.  
The conclusion reached through this study was that HbA1c levels and OGTT results 
largely categorized different individuals as having DM and pre-DM. The total 
prevalence of DM and pre-DM was higher based on HbA1c values than based on 
OGTT results.  
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4.2 Paper II – Evaluation of DM prevalence and mortality with 
respect to glycaemic status in patients with abdominal aortic 
aneurysms.  
In Paper II, the aim was to investigate the prevalence of DM and intermediate 
hyperglycaemia in AAA patients and to evaluate mortality with respect to glycaemic 
status assessed by HbA1c and OGTT measurements. Survival analyses were 
performed by using multivariate Cox-regression models.  
The total prevalence of known and newly diagnosed DM in this study population was 
23% based on OGTT results. Seven of the 66 AAA patients had known DM at 
baseline. The prevalence of newly diagnosed DM in 58 AAA patients of unknown 
glycaemic status at baseline was 12% (OGTT results) and 14% (HbA1c results) 
respectively. Compared with OGTT results, HbA1c values classified DM patients with 
43% sensitivity and 90% specificity. The prevalence of intermediate hyperglycaemia 
(pre-DM) was 43% based on OGTT results and 72% based on HbA1c values.  
Mean follow-up time was 71 months [0-100] (5.9 years). Total mortality in the 58 
AAA patients without known DM at baseline was 43%.   
HbA1c was a significant independent predictor for mortality in the DM category, 
adjusted HR 6.35, (95% CI 1.49-27.1); p=0.01.  
Compared with patients alive at study closure, patients who died during follow-up 
were older, had higher prevalence of cerebrovascular disease at baseline and were 
more likely to be treated with an endovascular procedure. Patients who received 
antiplatelet therapy at baseline had significantly higher total survival than those not 
treated.  
We concluded that AAA patients had high DM prevalence and half the patients were 
unaware of their DM diagnosis. DM defined by HbA1c ≥48 mmol/mol (6.5%) is 
associated with a lower survival-rate following surgical treatment for AAA. HbA1c 
may thus be important in pre-operative risk assessment of AAA patients. 
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4.3 Paper III – Evaluation of HbA1c and the OGTT as predictors 
for long-term mortality in vascular surgery patients of unknown 
glycaemic status. 
The main objective of Paper III was to evaluate HbA1c, FPG and 2-hour-post glucose 
load value as predictors for long-term mortality in 273 vascular surgery patients of 
unknown glycaemic status. Cox regression models were used to explore the 
associations of HbA1c and OGTT glycaemic categories with all-cause mortality. 
Mean follow-up time was 2805 days [0-3779] (9.2 years). All-cause mortality in the 
study population was 40%, and higher for AAA patients (55%) and patients with 
infra-inguinal occlusive disease (45%) than for those with carotid stenosis (24%) and 
IOD (15%).  
Compared with patients being alive at study closure, patients who died during follow-
up were older, had higher cardiovascular comorbidity and were less likely to use anti-
platelet therapy at baseline compared with patients being alive at study closure.  
HR of all-cause mortality according to HbA1c values was 1.54, (95% CI 1.03 – 2.32); 
p=0.04 when adjusted for age, sex and the use of platelet inhibitors, statins and 
antihypertensive medication. The OGTT was not an independent predictor for 
mortality.  
The results of this exploratory study suggest that HbA1c is a useful risk marker in 
preoperative screening of PAD patients of unknown glycaemic status at the time of 
admission for vascular surgery. Further research is needed to confirm these results 




5.1 Methodological Considerations  
This prospective cohort study of vascular surgery patients evaluated the performance 
of HbA1c for diagnosis of DM when using the OGTT (FPG and 2-h post glucose load 
value) as a gold standard.  Further, the associations between HbA1c, FPG and 2-hour 
post glucose load values, and all-cause mortality during follow-up were assessed.  
5.1.1 Study Population 
In this research project, patients with advanced atherosclerotic disease and unknown 
glycaemic status were studied. The vascular pathologies were carotid stenosis, AAA 
and peripheral occlusive disease including IOD and infrainguinal occlusive disease. 
Gender distributions and the presence of risk factors and vascular comorbidities in 
our study population were consistent with findings from other studies on vascular 
surgery patients86, 108, 122, 127-129. The authors therefore believe that the results from this 
study regarding diagnosis of DM are applicable on vascular surgery patients with 
advanced disease. The results are not necessarily applicable on patients with a milder 
form of vascular disease. Since the development of DM is a continuum from low risk 
to overt DM53, the high prevalence of DM and pre-DM based on HbA1c results may 
indicate a high degree of dysglycaemia even in patients with less advanced vascular 
disease. This implies a possibility that the results from this study-population may be 
relevant for vascular surgery patients with less advanced vascular disease.  
Former studies of PAD patients include patients having various mixtures of 
glucometabolic states; DM, pre-DM, normoglycaemia and mixed populations. In this 
research project, patients of unknown glycaemic status were all tested using HbA1c, 
FPG and OGTT measurements and included in the survival analyses. Hence, no 




A high number of non-attendants may have introduced a selection bias to this 
research project. Selection bias due to non-response or non-attendance may 
contribute to a bias of estimates if the non-attendants differ from the study 
participants130. Based on information from the Norwegian Cardiovascular Disease 
Registry, an analysis of the non-attendants was performed. Evaluation of mean FPG 
level, age, gender and vascular pathology showed that patients who died before 
deciding whether to participate were older (median age 82.0 years) and more likely to 
have infrainguinal occlusive disease compared with the study population. In 
comparison to the study participants, a higher percentage of patients who were 
excluded from the study due to missing OGTTs had inguinal occlusive disease and a 
higher percentage of patients who declined to participate were female. Mean FPG at 
baseline was the same for participants and non-participants.  
The fact that 21 patients died before deciding whether to participate may reflect too 
wide inclusion-criteria. The 21 patients had reached average life expectancy in 
Norway and were therefore not necessarily representative for the population in this 
study or vascular surgery patients in general36. If included in the study, the patients 
would represent only six percent of the study population. A selection bias regarding 
patients with infra-inguinal occlusive disease is believed to have only minor influence 
on results although it cannot be excluded.  
Mortality in the 33 patients who were excluded from this study due to missing OGTT 
values was 55% at study closure on the 30th of August 2016. This was higher 
compared with 40% mortality in the study population. Of the 33 patients with missing 
OGTTs, 15 patients were alive at study closure. Ninety-three percent of those patients 
had normal FPG level at baseline compared to 78% of the patients with missing 
OGTTs who were dead at study closure.  
In contrast, 61% of the patients with missing OGTTs who died had normal HbA1c 
level at baseline compared to 27% of the 15 patients who were alive at study closure. 
Half of the patients having normal FPG levels had pre-DM according to HbA1c 
values. Only one patient fulfilled DM criteria with HbA1c ≥6.5%. Hence, the 
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association of glycaemic status with mortality may have been underestimated in 
patients with IOD since patients with missing OGTTs were more likely to have 
inguinal occlusive disease.  
5.1.3 Classification of Vascular Pathologies 
Long-term survival rate varies according to affected vascular bed87. Mortality in 
patients with carotid stenosis is reported to be 10-20% in a 5-year time period127, 131 
whilst for AAA patients it is 40-50%132, 133. Mortality in patients with peripheral 
occlusive disease is 40-50% in five years113, 134-136. A study from Finland revealed a 
higher mortality in patients with crural occlusive disease as compared with proximal 
occlusive disease classified according to TASC II137. Hence, misclassification of 
patients may have impact on results of survival analyses. Further, a unified 
classification of the vascular pathologies according to joint guidelines would make 
research results comparable across studies. 
In the present research project, the authors considered to classify patients with 
peripheral occlusive disease by affected arterial segments according to TASC II. The 
authors also discussed to classifying those patients by symptoms according to 
Rutherford88. However, since such sub-classification was not accounted for prior to 
inclusion of patients in the study, the study did not have statistical power to perform 
analysis on the suggested categories. 
5.1.4 Diagnostic Tests 
When screening a population for a disease, high specificity and negative predictive 
value are preferable properties for the diagnostic test used. Specificity is defined as 
true negatives divided by true negatives plus false positives. Negative predictive 
value is defined as true negatives divided by true negatives + false negatives130. In 
concordance with other studies, results from this study found that HbA1c level had 
high specificity (90%) and high negative predictive value (92%) when using the 
OGTT as the gold standard. As recommended by the WHO, confirmative testing 
should be performed following a positive test result from the initial screening test 
used for the diagnosis of DM58. Only single measurements of HbA1c, FPG and 2-hour 
 40
post glucose load values were used in this research project. The FPG and 2-hour post 
glucose load values are known to have moderate reproducibility after retesting53, 68. 
Only half of those having pre-DM according to first FPG or 2-hour post glucose load 
value had pre-DM following repeated testing68. The majority of patients that were 
reclassified had normal FPG level or 2-hour post-glucose load value. Single 
measurements may have affected the categorization of patients into different 
glycaemic categories in our study. However, large epidemiological studies have used 
results from single measurements, thus making the results from this study comparable 
to other studies.  
The step from a diagnostic test result until diagnostic decision-making also involves 
considerations regarding analytical information about the test used. Standardization 
of the HbA1c assay has been essential to the implementation of HbA1c as a diagnostic 
test for DM. The HbA1c assays used in this study were standardized according to a 
National Glycohaemoglobin Standardization Program (NGSP)-certified method 
referenced to the DCCT trial. Pre-analytical handling and analysis of the plasma 
glucose tests were largely performed according to WHO recommendations53.  
When the diagnosis of DM is established, further classification into different types of 
DM is based on measurements of auto-antibodies and evaluation of phenotype. Auto-
antibodies are used to differentiate between DM Type 2 and latent autoimmune 
diabetes of adult (LADA). DM related auto-antibodies were not measured in this 
research project. Hence, we could not differentiate between DM type 2 and LADA. 
However, the presence of autoantibodies is associated with a more rapid decline in 
beta-cell function and mass and increased need for early intensive treatment 
compared to having negative auto-antibodies53, 57. Since only nine of the 33 patients 
with newly diagnosed DM by OGTT results received anti-diabetic therapy at the end 
of the study, it is most likely that patients in this study had DM Type 2 although the 
possibility of patients having LADA cannot be excluded. 
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5.2 Discussion of Results 
It is important to emphasise that this research project was not designed to explore 
causality for the association of glycaemic status and all-cause mortality, nor for the 
observed discordance in classification of patients into glycaemic categories according 
to HbA1c and OGTT results. Hence, the presented discussion and suggested 
explanations are literature-based speculations.   
5.2.1 Differences in Classification into Glycaemic Categories 
Changes in diagnostic methods and criteria over time affect DM prevalence and 
incidence. The first diagnostic approach to DM was based on the sweet taste of 
urine10. Urine testing was gradually replaced by blood testing through the 20th 
century64 and diagnostic limits for the diagnosis of DM were eventually introduced 
based on quantifying blood glucose in a fasting state and post glucose challenge138. 
Following the implementation of blood glucose testing through the 20th century, the 
diagnostic cut offs for DM have been debated and revised several times. The use of 
HbA1c for the diagnosis of DM was added to the debate in the late 1990’s139. 
However, lack of standardization of the HbA1c assay postponed the implementation 
of HbA1c as a diagnostic criterion until 200971. HbA1c was implemented to improve 
and facilitate the diagnosis of DM since glucose measurements have high variability, 
and the OGTT has low reproducibility and is inconvenient to perform58, 68. HbA1c has 
most of the preferred requirements for a diagnostic test. HbA1c is easily available, has 
low costs, is easy to use, has the ability to provide reliable results with high 
specificity, and has the ability to provide reliable prognostic information58, 140.  
Research has shown that using HbA1c criteria for the diagnosis of DM results in a 
lower prevalence of DM in general populations and populations at risk of developing 
DM compared to the OGTT criteria96, 103-106. According to the results from this 
research project, using HbA1c levels gave the highest prevalence of DM and pre-DM 
compared to when using OGTT criteria. This is in concordance with the findings in a 
multi-ethnic cohort, in a Chinese population and from the Tromsø OGTT study141-143. 
However, the participants in the Tromsø OGTT study were preselected based on 
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HbA1c values, which may have led to skewed estimations. On the contrary, Doerr et 
al found a lower prevalence of newly detected diabetes in CAD patients when using 
HbA1c criteria compared to when using OGTT criteria105.  This was confirmed in the 
Euroaspire IV study by screening CAD patients for DM using both HbA1c and OGTT 
measurements. Ninety-six percent of patients with newly diagnosed DM were 
identified by OGTT results whereas HbA1c detected 17%144. Hence, implementing 
HbA1c as a diagnostic test for the diagnosis of DM has had inconsistent impact on 
DM prevalence in different populations.  
Particularly high is the number of patients categorized as having pre-DM according to 
HbA1c results as compared with OGTT results in this research project. In Paper I, an 
HbA1c range of 5.7-6.4% for the diagnosis of pre-DM was used. This was in 
accordance with ADA’s criteria for the diagnosis of pre-DM. However, in 2011 the 
WHO implemented an HbA1c range of 6.0-6.4% for pre-DM58. Using WHO criteria, 
121 (45%) patients had pre-DM according to HbA1c results and 111 (41%) had 
normal HbA1c (Paper III, Table 1). The corresponding number of pre-DM patients 
was 193 (70%) and that of normal HbA1c was 42 (15%) when using ADA criteria 
(Paper I, Table 3). The OGTT results defined 90 (34%) patients as having pre-DM. 
Normo-glycaemia was found in 55% according to OGTT results. In conclusion, the 
prevalence of pre-DM in patients having advanced peripheral arterial disease is 
higher based on the by ADA and WHO proposed HbA1c ranges than based on OGTT 
results.  
Prediction of clinical consequences of a positive test-result must be added to the 
evaluation of the diagnostic tests used for clinical decision-making145. According to 
the 2010 ADA guidelines and the 2011 WHO statement on the use of HbA1c for the 
diagnosis of DM, patients having pre-DM or DM of HbA1c < 53 mmol/mol (7.0%) 
are recommended lifestyle interventions and annual monitoring of glucose status58, 59. 
According to the results from this research project, using HbA1c as the diagnostic test 
for the diagnosis of DM will imply a substantially higher number of patients in need 
for a close clinical follow-up compared to when using the OGTT. 
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The performance of a diagnostic test may be affected by the pre-test probability in the 
population tested130. In a population with low pre-test probability regarding a specific 
disease, a diagnostic test of high sensitivity to detect the disease will have low 
positive predictive value. The prevalence of DM and pre-DM is substantially higher 
in patients with peripheral vascular disease compared to in general populations at 
corresponding age groups45, 93, 97, 99.  Hence, the pre-test probability for DM in 
patients with peripheral vascular disease is high.   
In general populations, pre-DM according to OGTT results is more common than 
pre-DM according to HbA1c criteria103, 146. Thus, pre-test probability of pre-DM 
defined by OGTT results is higher than when based on HbA1c levels. This may imply 
that the OGTT has a higher positive predictive value than HbA1c when identifying 
pre-diabetic individuals in general populations. As opposed to the results from 
general populations, pre-DM in this study was substantially higher based on HbA1c 
results than based on OGTT results. This may imply that HbA1c has a higher positive 
predictive value when identifying pre-diabetic vascular surgery patients than the 
OGTT, and hence would be the preferred test to use in this group of patients. 
However, this assumption pre-supposes a close to equal sensitivity and specificity of 
HbA1c and the OGTT when used as diagnostic tests.  
5.2.2 Diagnostic Cut-off 
To evaluate if a diagnostic test is clinically valuable, the test’s discriminative ability 
to tell if a person has a disease or not must be considered. 
Test results may have a binary or a continuous outcome. The development of DM is 
seen as a continuum from normoglycaemia to overt DM53. Hence, measurements of 
FPG, 2-hour post glucose value and HBA1c have continuous outcomes varying from 
low risk of DM to overt disease. Implementation of a diagnostic cut-off for clinical 
decision-making may be used when a diagnosis is based on continuous variables. 
However, to choose a clinically useful cut-off may be challenging. The cut-offs for 
diagnosing DM are based on thresholds for increased risk of retinopathy although 
there is no definite division between a healthy stage and DM71, 75.  
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In this study, HbA1c had low sensitivity (45.5%) and positive predictive value (38%) 
for the diagnosis of DM compared with OGTT results. However, these calculations 
are based on a diagnostic cut off which in theory defines a person as either sick or 
healthy. Interpretation of a clinical cut off may be challenging. A person standing 
with one foot aligned with the diagnostic limit for DM and the other foot next to the 
first, will probably have close to equal risk of cardiovascular complications as a 
person standing just across the diagnostic limit.  
Introduction of a high-risk group may be used to address the problems using a 
diagnostic cut-off for continuous measurements. A high-risk range of HbA1c, FPG 
and 2-hour post glucose load value is established instead of a precise lower cut-off 58. 
In this research project, patients were classified into different glycaemic categories 
according to cut-offs defined by the WHO and ADA53, 57. However, when exploring 
the association of diagnostic parameters with mortality, HbA1c, FPG and 2-hour value 
were used as continuous variables. The use of continuous variables provides a more 
realistic model since the relationship of the diagnostic parameters with DM is linear. 
The optimal retinopathy-based cut offs for the diagnosis of DM is not consistent in 
different studies, and DM cut-offs are arbitrary since the development of DM is a 
continuum. Also, the use of continuous variables in a regression analysis provides a 
greater precision and power from a statistical point of view147. Hence, the results 
regarding association of HbA1c and the OGTT with mortality are not affected by the 
use of a diagnostic cut-off.  
5.2.3 The Use of a Gold Standard in Clinical Decision-making 
A receiver operating characteristic (ROC) curve may be used to evaluate and picture 
the performance of a continuous variable for a specific diagnosis.   
The Receiver Operating Characteristic curve was developed during the Second World 
War by plotting radar-operators’ evaluations of radio signals against arriving enemy 
aircraft. In medicine, the ROC curve was introduced in a variety of areas to assist 
clinical decision-making by evaluating diagnostic tests148.  
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The use of a cut off categorizing obtained data as positive and negative is the basis 
for calculating a ROC curve149. Every point in the ROC curve may be described as a 
trade-off between sensitivity and specificity. 
However, a challenge in medicine is how to define a pathological condition. 
Information retrieved by the ROC curve will depend on the parameter used as the 
gold standard. The OGTT was used as the gold standard for the diagnosis of DM in 
this research project. The results of the study showed an area under the curve (AUC) 
of 0.73, which may be considered moderate performance of HbA1c compared with the 
OGTT. 
A problem using a gold standard is that all other tests will be inferior150. The use of 
an external parameter linked to the relevant condition could bypass the problem 
regarding the use of a gold standard. Diagnostic cut offs for DM are based on the 
presence of retinopathy53, 58. Therefore, the presence of retinopathy obtained by 
fundus photography is a possible external parameter to be used when evaluating the 
performance of HbA1c for the diagnosis of DM in comparison with the OGTT. As 
stated earlier, the main contributors to the disease burden related to DM and vascular 
diseases are dysglycaemia, hypertension, dyslipidemia, high BMI and smoking. In a 
Chinese population, Peng et al found that patients diagnosed with DM solely based 
on HbA1c ≥ 48 mmol/mol (6.5%) had the worst cardiovascular risk profile142. Hence, 
instead of using the OGTT as a gold standard, a metabolic risk profile could be used 
as an external parameter when evaluating HbA1c versus the OGTT for the diagnosis 
of DM. 
5.2.4 Pathophysiological Differences between HbA1c and the OGTT 
The limited concordance between glycaemic categories according to HbA1c, FPG and 
2-h post glucose load results may to some extent be explained by differences in 
pathophysiological mechanisms of the tests.  
The 2-h post-glucose load value following an OGTT represents a stress test of beta-
cell functioning. By reflecting the average blood glucose level over the past 8-12 
weeks, HbA1c is a marker of chronic glycaemia.   
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Insulin resistance is a key feature in the pathophysiology of DM. Hepatic insulin 
resistance is the main contributor to fasting hyperglycaemia by elevated hepatic 
glucose output and impaired early insulin secretion. A pattern of insulin resistance in 
muscle and adipose tissue combined with impaired late phase insulin secretion is 
characteristic of postprandial hyperglycaemia151. The result is prolonged post glucose 
load hyperglycaemia. Patients with combined elevated FPG level and 2-hour post 
glucose load value have a worse metabolic profile than those patients having fasting 
hyperglycaemia or 2-hour hyperglycaemia only151, 152. Also, metabolic changes 
precede a diagnosis of DM by several years125.  
In the Tromsø OGTT study, patients with solely OGTT-defined pre-DM had a worse 
metabolic risk profile than patients having pre-DM by HbA1c results only143. 
However, in a study from China, OGTT negative patients with DM by HbA1c results 
were older, had higher prevalence of CAD, HT and obesity, and were more likely to 
be smokers compared with OGTT positive patients with normal HbA1c142.   
Based on a healthy population, the National type 2 diabetes prevention programme in 
Finland (Fin-D2D)-study found that a specific HbA1c level implied relatively higher 
2-hour post glucose and slightly lower FPG in older individuals when compared to in 
younger individuals153. Also, studies have shown that HbA1c and FPG correlates 
stronger for higher levels of HbA1c than for lower70. 
In the study-population of this study, advanced vascular disease and a high degree of 
vascular comorbidities precedes the diagnosis of DM and pre-DM. Vascular 
inflammation is a key element in endothelial dysfunction in DM9, 154. Studies have 
described an association of HbA1c with endothelial dysfunction both in persons with 
DM and in non-diabetic persons 154-156. In non-diabetic individuals, an association of 
inflammatory markers at baseline with increase in HbA1c levels during a seven years 
follow-up was shown154. 
To speculate, DM diagnosed using glucose criteria (fasting plasma glucose and 2-
hour post glucose load results) may represent a moderate age-related DM and 
therefore have little impact on long-term mortality risk. In contrast, HbA1c expresses 
long-term exposure to glucose and is linked to the degree of vascular inflammation. 
 47 
HbA1c may thus act as a surrogate marker for a worse metabolic profile in patients 
with advanced vascular disease and, therefore, be related to a higher risk of a shorter 
lifespan. 
5.2.5 Association of HbA1c and OGTT Categories with Long-term 
Mortality 
The survival rate in vascular surgery patients is three to five times lower than that of a 
general population at corresponding age groups and twice lower than that of patients 
with advanced CAD112, 157-160. Patients with both arterial disease and DM have higher 
mortality compared to patients with arterial disease only44. Cardiovascular diseases 
are a main contributor to fatal health-loss (death and years of life lost) in people with 
DM as well as in people with macrovascular diseases36, 113, 118.  
Results from this research project showed that HbA1c was associated with all-cause 
mortality both in patients with AAA and in the total study population of vascular 
surgery patients (Paper II and Paper III). While the results remained statistically 
significant for AAA patients in a multi-adjusted model, the association of HbA1c with 
all-cause mortality in the total study-population of vascular surgery patients did not 
achieve statistical significance after multiple adjustments. However, the effect size 
remained mainly unchanged. 
When evaluating results from a statistical analysis, the size of the measured effect and 
the precision of the estimates must be considered in addition to the p-value161. The p-
value represents the probability of an observed value in the context of the null 
hypothesis. However, the size of the p-value does not necessarily imply a certain 
effect of the observed value. In statistical calculations, a large effect can produce a 
high p-value if the sample size is small. On the contrary, a small effect can produce a 
low p-value if the sample size is large enough.  
In this study, HbA1c was an independent predictor for all-cause mortality in Cox 
regression Model 1 and Model 2 (Paper III). Given a HR of 1.39, lack of statistical 
power due to an insufficient sample size could explain the high p-value in Cox 
regression Model 3. To be added, the 95% CI of the calculated HRs reflects an 
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acceptable precision of the estimates. This might indicate a preserved association of 
HbA1c with mortality in a multivariate model. The authors therefore hypothesize that 
HbA1c may be a useful marker to identify persons at high risk of long-term mortality 
following surgical treatment for peripheral arterial disease.  
Professor Rydén et al. reported “abnormal glucose tolerance as an important predictor 
of long-term outcome after myocardial infarction”162. According to OGTT results in 
this research project, patients identified with pre-DM had higher mortality compared 
with normoglycaemic patients in crude analysis as pictured by the Kaplan-Meyer 
survival curve.  Patients with DM tended to have higher survival-rate than patients 
with pre-DM. Compared with normoglycaemic patients, patients having intermediate 
hyperglycaemia by OGTT results were more likely to be former or current smokers. 
We did not assess smoking status at time of study closure. However, it is possible that 
a higher percentage of patients diagnosed with DM ceased to smoke. Therefore, an 
“exposure-to-risk” bias as a possible explanation for the differences in survival 
cannot be excluded. In concordance with results from this study, pre-DM according 
to preoperative OGTT in Dutch vascular surgery patients was associated with 
increased risk of cardiovascular events and cardiovascular death when compared to 
normoglycaemic patients and patients with DM163. However, results from a large 
study cohort of Chinese CAD patients shows that patients with newly diagnosed DM 
by OGTT results have lower survival rate compared to patients having pre-DM. Both 
pre-DM and DM were associated with cardiovascular mortality164. Results from the 
Diabetes epidemiology: collaborative analysis of diagnostic criteria in Europe 
(DECODE) study group showed that patients with pre-DM and previously unknown 
DM from OGTT criteria had higher 9-year mortality compared with normoglycaemic 
patients. Patients with DM had the highest mortality165. Both the OGTT and HbA1c 
were found to be predictors of CVD mortality in a long-term follow-up, whereas only 
the OGTT was a predictor of all-cause mortality166.  
The results of this study and the study on Dutch CAD patients regarding higher 
mortality in pre-DM patients by OGTT results may be affected by an insufficient 
sample size.  
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In addition, in this study, patients with DM by OGTT results were informed about 
their DM diagnosis at baseline. At the time of inclusion in this study, HbA1c was not 
implemented as a diagnostic test for DM. Therefore, the 25 patients having HbA1c ≥ 
48mmol/mol (6.5%) and a non-DM OGTT result were not diagnosed with DM (Paper 
I, Table 3). Hence, the differences in treatment of DM are another possible 
explanation for the differences in mortality. On the other hand, only nine of the 
patients with DM according to OGTT results received medical treatment for DM at 
study closure. Of those, five had also DM by HbA1c results thus reducing the 
difference in medical treatment of DM between the groups. 
Regardless of the OGTT results, the HbA1c seems to be a useful marker for long-term 
mortality in vascular surgery patients. HbA1c should therefore be included when 




The following conclusions from this research project can be drawn based on the 
presented results and discussion: 
 
- Vascular surgery patients have high prevalence of undiagnosed DM and pre-DM.  
- The OGTT and HbA1c largely identify different patient groups as having DM and 
pre-DM. The number of vascular surgery patients having DM and pre-DM is higher 
based on HbA1c values than based on OGTT measurements. 
- In AAA patients of unknown glycaemic status, DM defined by HbA1c criteria is an 
important factor in mortality-risk assessment following surgical treatment for AAA.  
 
- In patients with advanced vascular disease and of unknown glycaemic status, HbA1c 
may be a useful marker to identify patients at high risk of lower survival rate 









7. Future Perspectives 
The results of observational studies provide information on associations between the 
parameters of interest and not on the causality behind the observed associations. 
Consequently, they may be described as hypothesis generating. To confirm the results 
from the mortality analyses in this research project and to evaluate whether or not the 
results are replicable for each of the vascular pathologies, further research on the 
association of glycaemic status with long-term survival in vascular surgery patients is 
needed. 
The link between the degree of chronic vascular inflammation and HbA1c levels as a 
possible explanation for the high prevalence of DM and pre-DM according to HbA1c 
results in patients with advanced vascular disease is an interesting aim for possible 
future research.  
Studies on animal models have demonstrated that incretin-based treatment suppresses 
the progression of atherosclerosis as well as having a marked anti-oxidative and anti-
inflammatory effect on endothelial cells81, 167. An incretin-based treatment study 
could provide additional information regarding HbA1c and inflammation in vascular 
surgery patients.  
In a comment to the 2007 update of TASC II, George Antoniou underlined the 
importance of an interdisciplinary cooperation in the management of PAD patients168. 
This research project was a cooperation between the Department of Vascular Surgery 
and the Department of Endocrinology Haukeland University Hostpital, 
Bergen,Norway. Following the results on AAA patients in this project (Paper II), a 
national study on AAA patients in Norway (the ABdominal ANeurysms and 
DIAbetes (ABANDIA) study) addressing dysglycaemia defined by HbA1c levels has 
been initiated.  
Further, Norgren et al. emphasized the importance of focusing on the assessment of 
patients’ comorbidities and risk factors in clinical handling of PAD patients4. 
Considering the gradual onset of DM and the fact that metabolic changes precede the 
diagnosis of DM, it may be implied that it is equally important to investigate pre-DM. 
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It also underlines the importance of making effort in early disease detection, 
improved classification of dysglycaemic PAD patients, and to risk-map the patients in 
order to provide tailored treatment.  
Hence, a national study on vascular surgery patients aiming to risk map the patients 
and facilitate DM diagnosis is most welcome.  
Finally, atherosclerosis is described as the common pathological process leading to 
both peripheral occlusive disease as well as aneurysmal disease. Most studies on 
patients with AAA have described a negative association of DM with the 
development of AAA although no causality is proven to explain these associations. 
Pericytes are supportive cells with contractile properties located around the 
endothelial cells. Pericytes have been linked to the development of DM 
retinopathy169-171. Studies aiming to explore whether altered pericyte qualities could 
explain part of the pathological differences between occlusive and aneurysmal 




Paper I, Table 1:  
The authors found errors in Table 1 after publication of the original article (Paper I). 
The correct values for medical history of coronary artery disease (CAD) at baseline 
were 110 (40%) of all patients, 55 (36.2%) of the patients were categorized as having 
normoglycaemia, 41 (45.6%) of the patients were categorized as having intermediate 
hyperglycaemia, and 14 (42.4%) of the patients were categorized as having DM. All 
presented numbers and calculations in Table 1 have been checked and no other errors 
were found. The presented errors did not affect the results, scientific content or 
conclusions. The published Erratum containing the corrected Table 1 is attached to 
this thesis.  
 
Paper II, Fig. 1: Correction to the figure legend for Fig. 1: The Kaplan Meyer curves 
picture overall survival in patients grouped according to HbA1c results (a) and OGTT 
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HbA1c versus oral glucose tolerance test as a
method to diagnose diabetes mellitus in vascular
surgery patients
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Abstract
Background: The diagnosis of diabetes mellitus (DM) is based on either fasting plasma glucose levels or an oral
glucose tolerance test (OGTT). Recently, an HbA1c value of ≥ 48 mmol/mol (6.5%) has been included as an
additional test to diagnose DM. The purpose of this study was to validate HbA1c versus OGTT as a method to
diagnose DM in vascular surgery patients.
Methods: The study population consisted of 345 patients admitted consecutively due to peripheral arterial disease.
Sixty-seven patients were previously diagnosed with DM. Glucose levels of OGTT and HbA1c values were analyzed
in 275 patients. The OGTT results were categorized into three groups according to the World Health Organization
1999 criteria: 1) DM defined as fasting plasma glucose (FPG) ≥ 7.0 mmol/L and/or two-hour value (2-h-value) ≥
11.1 mmol/L; 2) intermediate hyperglycaemia, which consists of IGT (FPG < 7.0 mmol/L and a 2-h-value between
7.8 mmol/L and 11.1 mmol/L), and IFG (fasting glucose value between 6.1 mmol/L and 7.0 mmol/L with a normal
2-h-value); and 3) normal glucose metabolism defined as FPG < 6.1 mmol/L and a 2-h-value < 7.8 mmol/L.
Results: Of the 275 patients on whom OGTT was performed, 33 were diagnosed with DM, 90 with intermediate
hyperglycaemia and 152 had normal glucose metabolism. An HbA1c value of ≥ 48 mmol/mol (6.5%) detected DM
with a 45.5% sensitivity and a 90% specificity compared with the OGTT results. Combining the measurements of
the HbA1c value with the fasting plasma glucose level (≥7.0 mmol/L) increased the sensitivity to 64%. The total
prevalence of DM and intermediate hyperglycaemia was 85% based on HbA1c values and 45% based on the OGTT.
Conclusions: Compared with the OGTT the HbA1c cut-off value of ≥ 48 mmol/mol (6.5%) had a 45.5% sensitivity to
diagnose DM in patients with peripheral arterial disease. OGTT and HbA1c categorized different individuals with DM
and intermediate hyperglycaemia. The total prevalence of pathologic glucose metabolism was substantially higher
based on HbA1c values than based on OGTT. The high prevalence of DM and intermediate hyperglycaemia when
using HbA1c in this study may reflect a high chronic glycaemic burden in patients with peripheral arterial disease.
Further studies on vascular surgery patients are needed to identify which method, OGTT or HbA1c, is the better in
predicting DM and future clinical development of vascular disease.
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Background
The diagnosis of diabetes mellitus (DM) has, until re-
cently, been based on blood glucose levels, i.e. either
fasting plasma glucose (FPG) ≥7.0 mmol/l or an oral glu-
cose tolerance test (OGTT) result of ≥11.1 mmol/l [1].
The HbA1c value reflects the average blood glucose
over a 2-3 month period and has traditionally been used
to evaluate the treatment of established DM. It has been
described as a predictor for DM and of micro- and
macrovascular disease [2-6]. Studies have shown a lin-
ear increase in retinopathy prevalence for HbA1c at
48 mmol/mol (6.5%) and above [7,8]. However, an in-
crease in retinopathy is also seen in the intermediate
hyperglycaemia (prediabetes) range of HbA1c and the
overall risk assessment for DM is seen as a continuum
from low risk to established DM [8].
The International Expert Committee of Diabetes,
American Diabetes Association and the World Health
Organization (WHO) have included HbA1c value ≥
48 mmol/mol (6.5%) as an additional method for diag-
nosing DM [8-10].
Two intermediate HbA1c ranges of 39-46 mmol/mol
(5.7-6.4%) (American Diabetes Association) and of 42-46
mmol/mol (6.0 – 6.4%) (the International Expert Com-
mittee) have been suggested to be used to identify indi-
viduals at high risk for developing DM [8,9]. The WHO
has not yet made a statement on the HbA1c diagnostic
range of intermediate hyperglycaemia.
Previous studies have revealed a higher prevalence of
DM in patients with peripheral arterial disease (PAD)
[11-13] compared to general populations [14-16] and
populations at risk of developing DM [17]. In all age
groups the prevalence of DM in Norway is estimated to
be 2.3%, with a prevalence of 3.4% among those aged
≥30 years. This increases with age to approximately 8%
amongst the elderly (70-79 years) [18]. Results from the
Nord-Trøndelag Diabetes Study indicate a prevalence of
IGT in Norway at 0.9% in men and 0.2% in women
using WHO 1980 criteria (IGT: 2-h-value between
8.0 mmol/L and 10.9 mmol/L). The study was based on
a pre selection of patients with an abnormal non-fasting
glucose value (≥ 8.0 mmol/L). The use of an initial
screening test and a threshold value for follow-up at
8.0 mmol/L may have led to an underestimation of the
total IGT prevalence[19]. The prevalence of impaired
fasting glucose (IFG) in Norway is not known. A prior
publication based on this study material revealed a
prevalence of pathologic glucose metabolism of 55% and
a frequency of diabetes of 29% among Norwegian vascu-
lar surgery patients [13].
Most studies that investigated the use of HbA1c values
against OGTT as a diagnostic tool for DM have found
reduced prevalence by HbA1c criteria compared with the
OGTT criteria. The studies also showed discordance
between OGTT and HbA1c values suggesting that
the two methods define different patient categories
[14-17,20,21]. Patients with PAD are multimorbid and
of high age[13]. It is important to evaluate whether re-
sults from studies on general populations and popula-
tions at risk of developing DM are applicable on this
high-risk population of patients with PAD. No previous
studies that have validated the use of HbA1c values
against OGTT in the diagnosis of DM in vascular sur-




This study was a prospective cohort study. The study
population consisted of 345 patients admitted consecu-
tively to the vascular surgery unit for elective surgery be-
tween October 2006 and September 2007. Initially 466
patients were asked to participate, however 121 declined.
DM was previously diagnosed in 67 patients (Figure 1).
This left data from 275 patients (273 ethnic Norwegians
and 2 white Europeans) for analyses. Informed written
consent was obtained from all participants. The research
Figure 1 Flow chart. The selection of patients admitted
consecutively to the vascular surgery unit at Haukeland University
Hospital, Norway, for elective surgery between October 2006 and
September 2007.
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protocol was approved by the Regional Committee for
Medical Research Ethics (REK vest 14109). The vascular
pathologies were peripheral arterial disease including
iliac occlusive disease (IOD), infrainguinal occlusive dis-
ease, abdominal aortic aneurismal disease and carotid
stenosis.
Diagnostic tests
An OGTT was performed on the 275 participating pa-
tients. Fasting glucose and HbA1c values were measured
in all patients. OGTT was performed after a minimum
of 8 hours overnight fasting, by orally administering a
standard dose of 75 g anhydrous glucose dissolved in
water. Plasma glucose levels were measured in a fasting
state prior to administering the anhydrous glucose and
again two hours after its administration. The patients
were not recommended any special diet prior to the
OGTT. In 61 patients (22%) the OGTT was performed
at their respective General Practitioner’s (GP’s) offices
due to logistic reasons. The results from these tests were
also analysed at their GP’s offices in 27 patients (44%), at
Haukeland University Hospital in 17 patients (28%) and
at other regional hospitals in 17 patients (28%). Venous
whole blood, drawn in containers with glycolytic inhibi-
tors (citrate and fluoride) and centrifuged within one
hour from venous sampling to separate plasma, was
used for the OGTT glucose measurements performed at
Haukeland University Hospital. Blood glucose during the
OGTT performed at the GP’s offices was analysed im-
mediately in capillary whole blood. The preanalytical
handling of the bloodsamples for the OGTTs performed
at other regional hospitals is not known.
The OGTT plasma glucose levels were analysed using
the available resources at the different hospital laborator-
ies: Modular P (Roche Diagnostics) (78% of the blood
samples were analysed using Modular P), Vitros 950
(Ortho-Clinical Diagnostics), Architect ci 8200 (Abbott),
Architect c 8000 (Abbott), and Hitachi 911 (Roche
Diagnostics). At the GP’s offices the following resources
were used for analysis: Hemocue 201+ (Photometer),
Hemocue B-glucose promedico and Reflotron +. The
range of the coefficients of variation on the equipment
used for glucose value analyses at the different hospital
laboratories was 1.8% -3.0%. Analytical discrepancies on
the equipment used for analysis at the GP´s offices were
referred to as accepted or not accepted, and were all
within accepted values set by NOKLUS.
External quality assessment of all equipment used for
analysis was performed by NOKLUS. NOKLUS is a
national institution certified by The National Institute
of Technology (NS-EN ISO 9001:2000), and run by
a committee consisting of representatives from The
Norwegian Crown, The Norwegian Medical Association
and The Norwegian Association of Local and Regional
Authorities. NOKLUS is quality checked by The Euro-
pean Reference Laboratory for Glycohemoglobin in the
Netherlands.
The OGTT results were categorized into three groups
according to the WHO 1999 criteria: 1) DM defined as
fasting plasma glucose (FPG) ≥ 7.0 mmol/l and/or two-
hour value (2-h-value) ≥ 11.1 mmol/l 2) intermediate
hyperglycaemia, which consists of IGT defined as FPG <
7.0 mmol/L and a 2-h-value between 7.8 mmol/L and
11.1 mmol/L, and IFG defined as fasting glucose value
between 6.1 mmol/L and 7.0 mmol/L with a normal 2-h
-value and 3) normal glucose metabolism defined as
FPG < 6.1 mmol/L and a 2-h-value < 7.8 mmol/L.
HbA1c values were measured on all participants through
a single blood sample, mainly at Haukeland University
Hospital (98% of the blood samples were analysed in the la-
boratory at Haukeland University Hospital using Variant II
HPLC system). Four patients were tested at their GP’s of-
fice, and three patients at other regional hospitals. HbA1c
values were then analysed using the following resources:
Variant II HPLC system (BioRad), DCA2000, DCAVantage
(Siemens), Hitachi 912 (Roche Diagnostics), D-10 (BioRad),
Nycocard reader (Axis-Shield) and Architect ci 8200
standardized immunoassay. The range of the coeffi-
cients of variation on the equipment used for HbA1c
level analyses was 0.8%-2.6% at HbA1c values 5.4%-9.8%.
Two bloodsamples were analysed on DCA 2000 with
coefficients of varation of 4.2%-5.2% at HbA1c 5.0%. The
analysing equipment used standardised assay in accord-
ance with DCCT standard.
The HbA1c results were categorized as: DM, intermedi-
ate hyperglycaemia and normoglycaemia. The diagnostic
limit of HbA1c is ≥48 mmol/mol (6.5%) according to
WHO statement 2011. The American Diabetes Association
definition of intermediate hyperglycaemia at 39-46 mmol/
mol (5.7-6.4%) was used since WHO has not yet made a
statement on the HbA1c diagnostic range of intermediate
hyperglycaemia.
Other variables
Information about age (continuous), sex (men/women),
smoking habits (yes/no), affected vascular bed, state of an-
aemia (yes/no) and kidney failure (yes/no) was obtained
from the patients’ medical records. The presence of kidney
failure and anaemia was defined based on estimated glom-
erular filtration rates and serum haemoglobin levels. Esti-
mated GFR values were calculated by The Modification of
Diet in Renal Disease equation. According to international
recommendations all patients treated at the Vascular
Surgery Department were given statins and anti-platelet
medication, unless strong contraindications were present.
Angiotensin Converting Enzyme Inhibitor/Angiotensin re-
ceptor blocker was the preferable choice when treating
hypertension.
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Statistical analysis
Data were analysed using SAS version 9.2 (SAS Institute,
Inc., Cary, North Carolina) and R version 2.8.1 (The R
Foundation for Statistical Computing, www.r-project.
org) software for Windows. All p values were 2-sided,
and values <0.05 were considered statistically significant.
The data is presented as mean±standard error for
continuous data and as percentage±standard error for
categorical data. Correlation between pairs of continuous
measures was calculated using the Spearmans correl-
ation coefficient. Associations between categorical vari-
ables were analysed using χ2 test. When the expected
number of observations in one or more categories was ≤ 5,
we used the Fisher’s exact test.
Segmented regression analysis (the segmented package
in R) was used to examine the association between the
Table 1 Baseline characteristics of the study population
Characteristics OGTT
All Normo- Intermediate Diabetes P-
patients glycaemia hyperglycaemia mellitus valuea
Total 275 152 90 33
Age, mean years 69.5 68.0 71.5 71.1 0.01
range] [35-89] [35-87] [48-89] [59-88]
Sex, n (%) 0.02
Female 74 (26.9) 51 (33.6) 15 (16.7) 8 (24.2)
Male 201 (73.1) 101 (66.5) 75 (83.3) 25 (75.8)
Smoking status, n (%) 0.06
Non-smoker 42 (15.3) 23 (15.1) 10 (11.1) 9 (27.3)
Former/current smoker 221 (80.4) 123 (80.9) 77 (85.6) 21 (63.6)
Missing 12 (4.36) 6 (3.95) 3 (3.33) 3 (9.09)
Renal function, n (%) 0.04
Normal (eGFR > 60) 201 (73.1) 120 (79.0) 57 (63.3) 24 (72.7)
Reduced (eGFR < 60) 71 (25.8) 31 (20.4) 31 (34.4) 9 (27.3)
Missing 3 (1.09) 1 (0.66) 2 (2.22)
Anemia female, n (%)
No anemia 61 (82.4) 43 (84.3) 10 (66.7) 8 (100) 0.52b
Female Hb < 11.7 g/dL 6 (8.11) 4 (7.84) 2 (13.3) 0
Missing 7 (9.46) 4 (7.84) 3 (13.3) 0
Anemia male, n (%)
No anemia 163 (81.1) 81 (81.2) 62 (82.7) 19 (76.0) 0.81b
Male Hb < 13.4 g/dL 29 (14.4) 16 (15.8) 9 (12.0) 4 (16.0)
Missing 9 (4.48) 3 (2.97) 4 (5.33) 2 (8.00)
Medical history of CAD, n (%) 0.67
No 231 (84.0) 129 (84.9) 73 (81.1) 29 (87.9)
Yes 42 (15.3) 22 (14.5) 16 (17.8) 4 (12.1)
Missing 2 (0.73) 1 (0.66) 1 (1.11) 0
Affected vascular bed, n (%) 0.16
Carotid 43 (15.6) 26 (17.1) 11 (12.2) 6 (18.2)
Aortic 59 (21.5) 30 (19.7) 23 (25.6) 6 (18.2)
IOD 50 (18.2) 35 (23.0) 9 (10.0) 6 (18.2)
Infrainguinal 123 (44.7) 61 (40.1) 47 (52.2) 15 (45.5)
Fasting glucose, mean mmol/L (SE) 5.70 (0.05) 5.27 (0.04) 5.90 (0.05) 7.11(0.24) <0.001
HbA1c, mean% (SE) 6.1 (0.03) 6.0 (0.03) 6.1 (0.05) 6.5 (0.13) <0.001
a Chi-square test for categorical data and Wald-test for continuous data.
b Fisher’s exact test.
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OGTT and the HbA1c values. This regression technique
provides separate regression coefficients for potential
piecewise linear relations. To estimate the breakpoint
between two segmented relations, the method uses in-
formation from the Davies’ test for a non-zero difference
in slope between variables. The HbA1c values in this
population ranged from 5% to 9%. Only five persons had
HbA1c value above 7%. Although the corresponding
glucose levels for the five patients were highly plausible,
potential outliers may have influenced the estimation of
cut-points in segmented regression. Therefore the seg-
mented regression analyses were performed with and
without these five subjects. No difference in estimated
cut-points was found, suggesting that patients with an
HbA1c value above 7% did not compromise the validity
of the present segmented regression.
Receiver operating characteristic (ROC) curves and
the area under the curve (AUC) were used to evaluate
the performance of HbA1c when using the OGTT cri-
teria as the gold standard. AUC was estimated for all
study participants, including the subpopulation where
HbA1c values were measured within one month after the
OGTT, and the subpopulation where HbA1c values were
measured within two months after the OGTT.
Results
Baseline characteristics of the study population are shown
in Table 1. According to the OGTTcriteria the prevalence
of DM was 12% and the prevalence of intermediate
hyperglycaemia was 33%.
The prevalence of reduced renal function was 20% in
the normoglycaemic group, 34% in the intermediate
hyperglycaemic group and 27% among the patients diag-
nosed with DM (p = 0.04). No statistically significant
relation between reduced renal function and HbA1c
values was seen (p = 0.46). The majority of the study
population was current or former smokers (80%). There
were no significant differences in OGTT values and
HbA1c values with respect to vessels tested (carotid,
aortic, iliac, infrainguinal) (p = 0.16). Separate analysis of
glycaemic categories according to HbA1c values revealed
no statistically significant differences in age, sex, smok-
ing status, renal function, anaemia, coronary heart dis-
ease or affected vascular bed.
Segmented regression analysis of FPG on HbA1c values
indicated a breakpoint at an HbA1c value of 45 mmol/
mol (6.3%) (95% CI 6.17, 6.51) in relation to FPG.
Segmented regression analysis of OGTT 2-h level on
HbA1c values showed a breakpoint on HbA1c value at
42 mmol/mol (6.0%) (95% CI 5.84, 6.18) in relation to
OGTT 2-h value. These statistically derived breakpoints
reveal a strong association between HbA1c values and
OGTT fasting plasma glucose values and OGTT 2 h-
values at HbA1cvalues 6.3% and 6.0% respectively,. This
emphasises the integrity of the data.
ROC analysis showed an association between OGTT
(gold standard) and HbA1c values (test variable) as diag-
nostic parameters for DM with AUC 0.73 (95% CI 0.63,
0.84). AUC was independent of the difference in timing
of blood sampling between OGTT results and HbA1c
values. There was no statistically significant association
between OGTT results and HbA1c values in the inter-
mediate hyperglycaemia category (AUC 0.56) (Table 2).
Table 3 shows the number of patients categorized as
having normoglycaemia, intermediate hyperglycaemia
and DM according to HbA1c values versus OGTT re-
sults, and the distribution of patients within the different
glycaemic categories. According to OGTT results, 33
patients had DM, 90 patients had intermediate hypergly-
caemia and 152 patients had normoglycaemia. Forty pa-
tients had DM according to HbA1c values. Fifteen
patients were diagnosed with DM by both criteria, giving
a sensitivity of 45.5%. The number of patients without
DM by either criterion was 217 (Figure 2a). Ninety pa-
tients had intermediate hyperglycaemia according to
OGTT results, and based on HbA1c values these were
classified similarly in 63% of the cases whereas 22% were
grouped as having DM (Table 3, Figure 2b). According
to HbA1c criteria 193 patients had intermediate hyper-
glycaemia. The number of patients without intermediate
hyperglycaemia by either criterion was 49 (Figure 2b).
HbA1c values combined with FPG classified 46 pa-
tients as having DM, and diagnosed DM with a sensitiv-
ity of 64% and specificity of 90%.
Discussion
The purpose of this study was to validate HbA1c as a
method to diagnose DM in vascular surgery patients by
comparing HbA1c values with the OGTT results. In this
study the prevalence of DM and intermediate hypergly-
caemia was higher based diagnosis through measuring
the HbA1c values compared with OGTT results (Table 3).
The two parameters defined the same individuals as
having diabetes in only 45.5% of the cases (Table 3,
Figure 2a). HbA1c combined with FPG had a higher sen-
sitivity (64%) compared to HbA1c alone. There was a sig-
nificant correlation between OGTT and reduced renal
function (p = 0.04). No such correlation was seen for
HbA1c.
This was a prospective study with a well-defined study
population of patients with advanced macrovascular dis-
ease. The selection of the study population was not
based on FPG values. As a result, patients with normal
FPG and elevated OGTT 2-h value were also diagnosed
correctly. HbA1c was measured in a standardised way to
ensure the accuracy of the values measured. Medical
conditions with abnormal red cell turnover may affect
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HbA1c measurement and give misleading results[1,22].
Haemoglobinopathies in Norway are mainly present in
persons with African or Asian ethnic origin [23]. The
study population was of European descent and there
were no significant differences in the prevalence of an-
aemia, suggesting that anaemia and abnormal haemoglo-
bin did not affect the validity of the results. The fact that
121 patients out of 467 declined to participate in the
study might introduce a selection bias. However, the
mean FPG values and the prevalence of DM based on
FPG levels alone were the same in the 121 patients as in
the study group.
Newly diagnosed DM
In contrast to most other studies an HbA1c value
≥48 mmol/mol (6.5%) was associated with a higher
prevalence of DM in this study when compared with
OGTT results (14.6% vs. 12.0%) (Table 3). The sensitiv-
ity of HbA1c compared with the OGTT in this study was
45.5%. Doerr et al performed coronary angiography in
patients with coronary heart disease and found a lower
prevalence of newly detected diabetes when using the
HbA1c criteria compared with the OGTT (4% vs. 14%)
[20]. Results from major epidemiological studies on gen-
eral populations also demonstrated a lower prevalence
of diabetes by HbA1c criteria compared with OGTT
[14-16]. This corresponds with results from studies on
populations at risk of developing DM [17,21]. A recent
metaanalysis demonstrated that performing an OGTT
during acute coronary syndrome did not impede the
diagnostic accuracy of the test. The study did not com-
pare HbA1c with the OGTT [24].
Similar to the results presented in this paper, Mostafa et
al found an increased prevalence of DM using HbA1c cri-
teria compared with the OGTT in a population based
study on a multi-ethnic cohort[25]. Several explanations
for the increased prevalence of DM by HbA1c criteria
in the population of vascular surgery patients may be
presented. HbA1c value measurements are influenced by
high age, male sex, kidney failure and ethnicity [8,22,26],
and pretest probability is influenced by the risk of DM de-
velopment. All factors were present in this study, except
that the study population consisted of white Europeans.
On the contrary, Martins et al found that in older adults,
females presented higher values of HbA1c than men, and
that HbA1c is not affected by age[27]. Participants with
IGT and/or DM were excluded.
Intermediate hyperglycaemia
An intermediate HbA1c value range has been suggested
to identify individuals in need for preventive interven-
tions [8,9]. An interesting observation in this study is
the high number of patients with intermediate hypergly-
caemia as defined by HbA1c in contrast to OGTT (70%
vs. 33%) (Figure 2b). The prevalence of intermediate
hyperglycaemia in the National Health and Nutrition
Table 2 Area under curve and summary statistics of HbA1c cut-off of 6.5 nmol/l for all patients, for patients with GFR
≥60 and for patients with GFR <60
Parameters All patients Where GFR≥ 60 Where GFR < 60
No. 275 201 74
Area under curve (95% CI) 0.73 (0.63, 0.84) 0.71 (0.57, 0.84) 0.78 (0.63, 0.94)
Sensitivity (95% CI) 0.45 (0.28, 0.64) 0.46 (0.26, 0.67) 0.44 (0.14, 0.79)
Specificity (95% CI) 0.90 (0.85, 0.93) 0.92 (0.87, 0.96) 0.83 (0.72, 0.91)
Positive predictive value (95% CI) 0.38 (0.23, 0.54) 0.44 (0.24, 0.65) 0.27 (0.08, 0.55)
Negative predictive value (95% CI) 0.92 (0.88, 0.95) 0.93 (0.88, 0.96) 0.92 (0.81, 0.97)
Table 3 The number of patients categorized as having normoglycaemia, intermediate hyperglycaemia and DM
according to HbA1c









Total 275 42 (15.3) 193 (70.2) 40 (14.6)
Normoglycaemia 152 27 (17.8) 120 (79.0) 5 (3.3)
Intermediate hyperglycaemia 90 13 (14.4) 57 (63.3) 20 (22.2)
Diabetes mellitus 33 2 (6.1) 16 (48.5) 15 (45.5)
a HbA1c ≥ 6.5% (48 mmol/mol) = diabetes mellitus, HbA1c range of 5.7-6.4% (39-46 mmol/mol) = intermediate hyperglycaemia, and
HbA1c < 5.7% (39 mmol/mol) = normoglycaemia.
b FPG + 2-h value. DM = FPG ≥ 7.0 mmol/l and/or two-h value ≥ 11.1 mmol/l. Intermediate hyperglycaemia = IGT defined as FPG < 7.0 mmol/L and a 2-h-value
between 7.8 mmol/L and 11.1 mmol/L, and IFG defined as fasting glucose value between 6.1 mmol/L and 7.0 mmol/L with a normal 2-h-value. Normoglycaemia =
FPG < 6.1 mmol/L and a 2-h-value < 7.8 mmol/L.
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Examination Survey using HbA1c criteria was one tenth
that of OGTT results [15]. In contrast, among coronary
heart disease patients the prevalence of intermediate
hyperglycaemia using HbA1c criteria was similar to that
of OGTT results [20]. Major prospective studies indicate
an increased risk of developing DM in patients within the
intermediate hyperglycaemia range of HbA1c [28-31].
Clinical interpretations
Existing literature is often challenging to interpret as pre-
vious studies were performed on various mixtures of study
populations; populations with diabetes, populations with-
out diabetes and mixed populations. This study was
performed on patients with advanced macrovascular dis-
ease and a mixture of glucometabolic states. HbA1c has
been considered as a risk predictor for subsequent dia-
betes and microvascular disease [2-5,28], and has been
proposed as a risk predictor for macrovascular disease in
people with DM [6,29]. However, studies on patients with
established coronary heart disease have shown that the
OGTT and not HbA1c is the best predictor for the
macrovascular disease [20,32,33]. Both this and previously
performed studies [14-17,20,21] have shown that the
OGTT and HbA1c define different categories of patients
as having DM and intermediate hyperglycaemia. HbA1c
describes long-term glycaemic burden and represents a
different metabolic expression to OGTT. The high preva-
lence of DM and intermediate hyperglycaemia when using
HbA1c in this study may reflect a high chronic glycaemic
burden in patients with peripheral arterial disease.
The clinical importance of the high number of patients
with DM and intermediate hyperglycaemia in this study
with advanced macrovascular disease, whether defined
by HbA1c or OGTT, is unknown. Future studies are
needed to identify which test, the OGTT or the HbA1c,
is the better in predicting the clinical outcome in
vascular surgery patients and in defining the patients in
need for treatment or preventive intervention.
Limitations
The sample size of this study with participants from a spe-
cific high-risk population was relatively small. The discord-
ance between OGTT results and HbA1c values reveald the
challenge when using a gold standard, i.e. that any other
test will be inferior. Ideally, it would be preferable to use an
external diagnostic and prognostic parameter, for example
the prevalence of retinopathy, in order to compare HbA1c
with the OGTT. Due to logistic reasons, some OGTTs
were not performed at standard conditions in the hospital
for all patients. This reflects the clinical reality where the
diagnosis of DM is mostly done by the primary health care
provider. For the same reasons, the HbA1c values were not
measured at the same time as the OGTT for all patients.
Separate analyses were performed on those patients who
had their HbA1c values measured between one month and
two months after the time that their OGTT was performed.
There were no significant differences in the results. It
would have been preferable to use the mean of two fasting
glucose levels, two two-hour glucose levels and two HbA1c
values for statistical analysis to secure reproducibility of the
results. The International Expert Committee, American
Diabetes Association and the WHO have suggested re-
peated HbA1c measurements as a diagnostic criterion for
type 2 DM [8-10]. However, large epidemiological studies
have used the results from one single measurement of
FPG, two-hour value and HbA1c, thus making the results
from this study comparable to other studies. Finally, it
would have been preferable to have used body mass index
as an adjustment variable, but this was not registered.
Conclusion
In vascular surgery patients an HbA1c value of ≥48 mmol/
mol (6.5%) had a 45.5% sensitivity, and a 90% specificity
Figure 2 Venn diagrams. a The prevalence of newly diagnosed DM by OGTT results (FPG≥ 7.0 mmol/l and/or 2-hour value≥ 11.1 mmol/l) (red
circle) and by HbA1c value≥ 6.5% (48 mmol/mol) (blue circle). The prevalence of diabetes mellitus was higher when using HbA1c criteria, and
HbA1c classified 46% of the 33 patients with newly diagnosed diabetes mellitus in concordance with OGTT results. b The prevalence of
intermediate hyperglycaemia by OGTT results (FPG 6.1 mmol/l – 7.0 mmol/l and/or 2-hour value 7.8 mmol/l – 11.1 mmol/l) (red circle) and by
HbA1c value 5.7% - 6.4% (39-46 mmol/mol) (blue circle). The prevalence of intermediate hyperglycaemia was higher when using HbA1c criteria
compared with OGTT results.
Hjellestad et al. Cardiovascular Diabetology 2013, 12:79 Page 7 of 9
http://www.cardiab.com/content/12/1/79
when compared to the OGTT when diagnosing DM. The
total prevalence of pathologic glucose metabolism was sub-
stantially higher based on HbA1c values than based on
OGTTs. The two parameters, the OGTT and the HbA1c,
categorized different individuals with DM and intermediate
hyperglycaemia. The high prevalence of DM and intermedi-
ate hyperglycaemia when using HbA1c values in this study
may reflect a high chronic glycaemic burden in patients
with peripheral arterial disease. Further studies on vascular
surgery patients are needed to identify which method, the
OGTT or the HbA1c, is the better in predicting DM and fu-
ture clinical development of vascular disease.
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The authors found errors in Table 1 after publication of 
the original article [1].
The correct values for medical history of coronary 
artery disease (CAD) at baseline are 110 (40%) of all 
patients, 54(35.5%) of patients categorized as having nor-
moglycaemia, 42(46.7%) of patients categorized as having 
intermediate hyperglycaemia, and 14 (42.4%) of patients 
categorized as having DM.
All presented numbers and calculations in Table  1 
are checked. No other errors were found. The pre-
sented errors did not affect results, scientific content or 
conclusions.
The corrected Table 1 is presented in this erratum.
The authors apologize for having presented this error 
in the original article.
Open Access
Cardiovascular Diabetology
*Correspondence:  iren.hjellestad@gmail.com 
1 Department of Medicine, Haukeland University Hospital, Jonas Lies vei 
65, 5021 Bergen, Norway
Full list of author information is available at the end of the article
Page 2 of 2Hjellestad et al. Cardiovasc Diabetol  (2018) 17:42 
Author details
1 Department of Medicine, Haukeland University Hospital, Jonas Lies vei 65, 
5021 Bergen, Norway. 2 Centre for Clinical Research, Haukeland University 
Hospital, Bergen, Norway. 3 Department of Clinical Sciences, University of Ber-
gen, Bergen, Norway. 4 Department of Vascular Surgery, Haukeland University 
Hospital, Bergen, Norway. 
Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in pub-
lished maps and institutional affiliations.
Received: 16 March 2018   Accepted: 16 March 2018
Reference
 1. Hjellestad ID, Astor MC, Nilsen RM, Softeland E, Jonung T.  HbA1c versus 
oral glucose tolerance test as a method to diagnose diabetes mellitus in 
vascular surgery patients. Cardiovasc Diabetol. 2013;12:79. https://doi.
org/10.1186/1475-2840-12-79
Table 1 Baseline characteristics of the study population
a Chi square test for categorical data and Wald-test for continuous data
b Fisher’s exact test
Characteristics All patients OGTT
Normo-glycaemia Intermediate hyperglycaemia Diabetes mellitus P-valuea
Total 275 152 90 33
Age, mean years [range] 69.5 [35–89] 68.0 [35–87] 71.5 [48–89] 71.1 [59–88] 0.01
Sex, n (%) 0.02
 Female 74 (26.9) 51 (33.6) 15 (16.7) 8 (24.2)
 Male 201 (73.1) 101 (66.5) 75 (83.3) 25 (75.8)
Smoking status, n (%) 0.06
 Non-smoker 42 (15.3) 23 (15.1) 10 (11.1) 9 (27.3)
 Former/current smoker 221 (80.4) 123 (80.9) 77 (85.6) 21 (63.6)
 Missing 12 (4.36) 6 (3.95) 3 (3.33) 3 (9.09)
Renal function, n (%) 0.04
 Normal (eGFR > 60) 201 (73.1) 120 (79.0) 57 (63.3) 24 (72.7)
 Kidney failure (eGFR < 60) 71 (25.8) 31 (20.4) 31 (34.4) 9 (27.3)
 Missing 3 (1.09) 1 (0.66) 2 (2.22)
Anemia female, n (%)
 No anemia 61 (82.4) 43 (84.3) 10 (66.7) 8 (100) 0.52b
 Female Hb < 11.7 g/dL 6 (8.11) 4 (7.84) 2 (13.3) 0
 Missing 7 (9.46) 4 (7.84) 3 (13.3) 0
Anemia male, n (%)
 No anemia 163 (81.1) 81 (81.2) 62 (82.7) 19 (76.0) 0.81b
 Male Hb < 13.4 g/dL 29 (14.4) 16 (15.8) 9 (12.0) 4 (16.0)
 Missing 9 (4.48) 3 (2.97) 4 (5.33) 2 (8.00)
Medical history of CAD, n (%) 0.34
 No 165 (60.0) 98 (64.5) 48 (53.3) 19 (57.6)
 Yes 110 (40.0) 54 (35.5) 42 (46.7) 14 (42.4)
Affected vascular bed, n (%) 0.16
 Carotid 43 (15.6) 26 (17.1) 11 (12.2) 6 (18.2)
 Aortic 59 (21.5) 30 (19.7) 23 (25.6) 6 (18.2)
 IOD 50 (18.2) 35 (23.0) 9 (10.0) 6 (18.2)
 Infrainguinal 123 (44.7) 61 (40.1) 47 (52.2) 15 (45.5)
Fasting glucose, mean mmol/L (SE) 5.70 (0.05) 5.27 (0.04) 5.90 (0.05) 7.11 (0.24) < 0.001
HbA1c, mean % (SE) 6.1 (0.03) 6.0 (0.03) 6.1 (0.05) 6.5 (0.13) < 0.001
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Aims: The prevalence of diabetes mellitus (DM) and mortality with respect to glycaemic status in patients
with abdominal aortic aneurysms (AAA) was evaluated. Glycaemic status was assessed by an oral glucose
tolerance test (OGTT) and by HbA1c.
Methods: Sixty-six patients with AAA admitted to the vascular surgery unit for elective surgery between
October 2006 and September 2007 were included. Seven patients had previously known DM. OGTT and HbA1c
results were available from 58 patients. The patients were categorized as having DM, prediabetes and
normoglycaemia according to the WHO's and American Diabetes Association's criteria.
Results: The prevalence of newly diagnosed DM according to the OGTT and HbA1c results were 12% and 14%
respectively. Mean follow-up time was 68 months and all-cause mortality 43%. HbA1c was an independent
predictor for mortality in the DM category. Hazard ratio of all-cause mortality in the DM category defined by
the HbA1c values was 6.35, 95% [CI 1.49–27.1]; p = 0.01.
Conclusions: DM defined by HbA1c ≥ 6.5% is an important determinant of mortality following surgical
treatment for AAA. Half the patients with AAA and DMwere unaware of their DM diagnosis. All patients with
AAA should be tested for DM using HbA1c. The results should be confirmed in a larger prospective study.
© 2016 Elsevier Inc. All rights reserved.
1. Introduction
The diagnosis of diabetes mellitus (DM) is defined as either
fasting plasma glucose levels (FPG) ≥ 7.0 mmol/L, and/or two-hour
oral glucose tolerance test (OGTT) ≥ 11.1 mmol/L or an HbA1c value
of ≥ 48 mmol/mol (6.5%) (American Diabetes Association, 2010;
World Health Organization, 2006).
Previous studies have revealed a higher DM prevalence in patients
with peripheral arterial disease (PAD) (Astor, Softeland, Daryapeyma,
& Jonung, 2010; Selvin & Erlinger, 2004) compared to general
populations (Cowie et al., 2006; Midthjell & CMYLCPSC, 2010) and
populations at risk of developing DM (Peter et al., 2011).
When comparing the diagnostic modalities for the diagnosis of
DM (HbA1c and the OGTT including FPG and/or 2 h-post glucose
value), it has been shown that they to a significant degree define
different individuals as having DM (Cowie et al., 2010; Doerr et al.,
2011; Hjellestad, Astor, Nilsen, Softeland, & Jonung, 2013; Lauritzen,
Sandbaek, Skriver, & Borch-Johnsen, 2011; Midthjell & CMYLCPSC,
2010; Peter et al., 2011; Rathmann et al., 2012). In a cohort of patients
with peripheral arterial disease located in western Norway, the total
prevalence of pathologic glucose metabolism was substantially
higher when based on HbA1c values than when based on the OGTT.
The two parameters largely defined different patients with DM
(Hjellestad et al., 2013). No studies could be found comparing the
prevalence of DM by the two criteria in patients with abdominal
aortic aneurysm (AAA).
Up to one third of patients with type 2 DM are unaware of their
DM diagnosis (World Health Organization, 2006), and are therefore
untreated and at high risk of developing vascular complications.
Patients with AAA and DM defined by OGTT have a higher risk of
complications and shorter long-term survival compared with AAA
patients without known DM - although studies have reported
inconsistent results (Theivacumar, Stephenson, Mistry, & Valenti,
2014). Further, the impact of DM and prediabetes on mortality
in patients with AAA, based on the OGTT and the HbA1c values, is
not known.
It is of vital importance to inform about the high level of
dysglycaemia in AAA patients to improve diagnostics and treatment
of dysglycaemia and improve clinical outcome.
The aim of this study was to evaluate the prevalence of DM and
prediabetes in AAA patients, and the mortality with respect to
glycaemic status assessed by OGTT and HbA1c.
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2. Methods
2.1. Patient Selection
This study was a prospective cohort study including patients with
abdominal aortic aneurysms admitted for surgical treatment for their
AAA. The initial study population consisted of 345 patients admitted
consecutively to the vascular surgery unit for elective surgery
between October 2006 and September 2007. The vascular pathologies
were carotid stenosis, AAA, iliac occlusive disease and infrainguinal
occlusive disease. Sixty-six of these patients had AAA, and were
included in the present study. Seven patients had previously known
DM. HbA1c value was missing in one patient. An OGTT was performed
on the remaining 58 patients and the results were included for further
analysis. Fasting glucose and HbA1c values were analyzed in all
patients. The research protocol was approved by the Regional
Committee for Medical Research Ethics (REK vest 14109).
2.2. Diagnostic Tests
An OGTT was performed on 58 patients. Fasting glucose and HbA1c
values were measured in all participants. The OGTT was performed by
orally administering a standard dose of 75 g anhydrous glucose
dissolved in water after a minimum of eight hours overnight fasting.
Plasma glucose levels were measured in a fasting state prior to
administering the anhydrous glucose and again two hours after
administration. Venous whole blood, drawn in containers with
glycolytic inhibitors (citrate and fluoride) and centrifuged within one
hour from venous sampling to separate plasma, was used for the OGTT
glucose measurements.
The OGTT plasma glucose levels were analysed using Modular P
(Roche Diagnostics). The OGTT results were categorized into three
groups according to the WHO 1999 criteria: 1/DM defined as fasting
plasma glucose (FPG) ≥ 7.0 mmol/l and/or two-hour value
(2-h-value) ≥ 11.1 mmol/l, 2/prediabetes, which consists of IGT
defined as FPG b 7.0 mmol/L and a 2-h-value between 7.8 mmol/L
and 11.1 mmol/L, and IFG defined as fasting glucose value between
6.1 mmol/L and 7.0 mmol/L with a normal 2-h-value and 3/normal
glucose metabolism defined as FPG b 6.1 mmol/L and a
2-h-value b 7.8 mmol/L.
HbA1c values were measured in all participants through a single
blood sample using Variant II HPLC system (Biorad). The HbA1c results
were categorized as: DM, prediabetes and normoglycaemia. The
diagnostic limit of HbA1c is ≥48 mmol/mol (6.5%) according to the
WHO statement of 2011. The American Diabetes Association definition
of prediabetes at 39–46 mmol/mol (5.7–6.4%) was used since the
WHO has not yet made a statement on the HbA1c diagnostic range
of prediabetes.
External quality assessment of all equipment used for analysis was
performed by NOKLUS. NOKLUS is a national institution certified by The
National Institute of Technology (NS-EN ISO 9001:2000), and run by a
committee consisting of representatives from The Norwegian Health
Ministry, The Norwegian Medical Association and The Norwegian
Association of Local and Regional Authorities. NOKLUS is quality
checked by The European Reference Laboratory for Glycohemoglobin
in the Netherlands.
2.3. Other Variables
Information about age (continuous), sex (men/women), smoking
habits (yes/no), aortic diameter (continuous), body mass index (BMI)
(kg/m2), state of anaemia (yes/no), reduced renal function (yes/no),
coronary artery disease (yes/no), cerebrovascular disease (yes/no),
established peripheral occlusive disease (yes/no) and medical
treatment (the use of statins, platelet inhibitors and antihypertensive
medication) (yes/no) at time of inclusion was obtained from the
patients' medical records. The presence of reduced renal function
was defined based on estimated glomerular filtration rates (eGFR),
calculated by The Modification of Diet in Renal Disease Equation.
Surgical treatment for AAA was either open surgery or an
endovascular procedure. Patients with high age and comorbidities
were more likely to be treated with an endovascular procedure while
younger patients and patients without comorbidities weremore likely
to be treated with open surgery.
2.4. End Points and Follow-Up
The study was closed on the 11th of August 2014. Mean follow-up
time of the study population was 71 months [range: 0–100].
Follow-up time for each participant was defined as the number of
months from the date of surgical intervention to the date of death, or
to the date of study closure. Mortality rates were verified by the
Norwegian civil registry. The primary end point was death of all cause.
2.5. Statistical Analysis
Data were analysed using R version 3.2.1 (R Core Team, 2015)
software for Windows. All p values were 2-sided, and values b0.05
were considered statistically significant. The data were presented as
mean ± standard error for continuous data, and as number and
percentage for categorical data. Associations between categorical
variables were analysed using χ2 test. When the expected number of
observations in one or more categories was ≤ 5, the Fisher's exact test
was used. The Kaplan–Meier survival function was used to describe
the percentage of survivors since study inclusion. To test for difference
in survival functions across glycaemic categories based on both the
OGTT and the HbA1c value, the log-rank test was used.
Associations of OGTT and HbA1c glycaemic categories with
all-cause mortality were further estimated as hazard ratios with 95%
confidence intervals (CIs) using Cox regressionmodels. The time from
study inclusion until death was used as the measure of event free
time. All patients were monitored until censoring with 11th of August
2014 as the final day of follow-up. The hazard ratios were estimated
by crude models as well as after controlling for age, platelet inhibitor
and statin. The three covariates were selected among 11 covariates,
measured at study inclusion, by using a stepwise method stated in
literature (Collet, 2015). The covariates initially explored were age,
the use of platelet inhibitor, BMI, sex, hypertension, reduced renal
function, coronary artery disease, smoking status, the use of statin, the
use of antihypertensive medication and established peripheral
occlusive disease. Based on a test and inspection of scaled Schoenfeld
residuals, it was verified that the proportional-hazards assumption
was fulfilled for all variables in the final models.
3. Results
Baseline characteristics of all participants are presented in Table 1.
The study population was an elderly population with a high
prevalence of comorbidities. The majority of the participants were
former or current smokers. Patients who died during follow-up had
significantly higher age and more often a history of cerebrovascular
disease at baseline. They were more likely to be treated with an
endovascular procedure than open surgery in comparison with
patients who were alive at end of the study.
3.1. Glycaemic Status
The prevalence of newly diagnosed DM, prediabetes and normogly-
caemia, in patients with AAA is summarized in Table 2. The HbA1c
criteria and the OGTT results largely classified different patients as
having newly diagnosed DM. The total prevalence of DM in this
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population was 23% based on the OGTT results and 25% based on the
HbA1c levels.
3.2. Mortality
Mean follow-up time was 71 months [range 0–100]. All-cause
mortality among the patients without previously diagnosed DM was
43%. The HbA1c, and not the OGTT, was a significant independent
predictor for mortality in the DM category (Fig. 1). Final adjusted
hazard ratio of all-cause mortality in the DM category defined by the
HbA1c values was 6.35, 95% [CI 1.49–27.1]; p = 0.01 (Table 3).
According to the OGTT results, patients with prediabetes and not with
DM had a significantly higher mortality rate during the course of the
study in crude analysis, HR 2.83, [CI 1.16–6.89]; p = 0.02. This
association did not achieve statistical significance after multivariate
analysis HR 2.28, [CI 0.84– 6.15]; p = 0.10 (Table 3).
3.3. Medical Treatment
At timeof inclusion, 85%of the studypopulation received statins, 76%
antiplatelet therapy, 10% warfarin and 86% received antihypertensive
treatment. Patients who were treated with antiplatelet therapy at
baseline had a significantly higher survival rate than those not treated.
Only one patientwith newly diagnosed DMusingOGTT results received
medical treatment for DM at the closure of the study. No patients with
newly diagnosed DM by HbA1c results received medical treatment for
DM at the closure of the study.
4. Discussion
The aim of this study was to evaluate the prevalence of DM,
prediabetes and mortality with respect to glycaemic status in patients
with AAA, by using the OGTT and the HbA1c values.
Table 1
Baseline characteristics.




















Female 8 (13.1) 4 (6.9) 1 (4.0) 3 (9.1) n.s.b























Open, n (%) 40 (60.6) 35 (60.3) 10 (40.0) 25 (75.8) 0.006
Endovascular, n (%) 25 (37.9) 22 (37.9) 15 (60.0) 7 (21.2) 0.003
Conservatively treated, n (%) 1 (1.5) 1 (1.7) 0 1 (3.0)
Smoking status, n (%)
Non-smoker 13 (19.7) 10 (17.2) 4 (16.0) 6 (18.2) n.s.b
Former/Current smoker 51 (77.3) 47 (81.1) 21 (84.0) 26 (78.8) n.s.
Missing 2 (3.0) 1 (1.7) 0 1 (3.0)
Renal function, n (%)
Normal (eGFR N 60) 49 (74.2) 43 (74.1) 17 (68.0) 26 (78.8) n.s
Reduced (eGFR b 60) 17 (25.8) 15 (25.9) 8 (32.0) 7 (21.2) n.s
Missing 0 0 0 0
Medical history of hypertension, n (%)
No 38 (57.6) 31 (53.4) 12 (48.0) 19 (57.6) n.s.
Yes 28 (42.4) 27 (46.6) 13 (52.0) 14 (42.4) n.s.
Missing 0 0
Medical history of CVD, n (%)
No 48 (72.7) 41 (70.7) 14 (56.0) 27 (81.8) 0.03
Yes 18 (27.3) 17 (29.3) 11 (44.0) 6 (18.2) 0.03
Missing 0
Medical history of CAD, n (%)
No 31(47.0) 29 (50.0) 11 (44.0) 18 (54.5) n.s.
Yes 35(53.0) 29 (50.0) 14 (56.0) 15 (45.5) n.s.
Missing 0 0 0






















CAD = coronary artery disease, CVD = cerebrovascular disease.
a Chi-square test. p-value refers to the association between patients dead during follow up and patients alive at the closure of the study.
b Fisher's exact test.
Table 2
The number of patients with AAA categorized as having normoglycaemia, prediabetes











OGTTb Normo-glycaemia 4 (15.4) 21 (80.8) 1 (3.8) 26 (44.8)
Prediabetes 3 (12.0) 18 (72.0) 4 (16.0) 25 (43.1)
Diabetes mellitus 1 (14.3) 3 (42.9) 3 (42.9) 7 (12.1)
Subjects 8 (13.8) 42 (72.4) 8 (13.8) 58
a HbA1c ≥ 6.5% (48 mmol/mol) = diabetes mellitus, HbA1c range of 5.7–6.4%
(39–46 mmol/mol) = prediabetes, and HbA1c b 5.7% (39 mmol/mol) = normoglycaemia.
b FPG + 2-h value.
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The results from this study provide new information about glycaemic
status and mortality in patients with AAA, and may have implications
for the medical treatment of diabetes and clinical outcome in patients
with AAA.
In this study, theprevalence of newly diagnosedDMaccording to the
OGTT and the HbA1c results were 12% and 14% respectively. The total
prevalence of DM in the study population was 23% based on the OGTT
results and 25% based on the HbA1c values. Mean follow-up time was
71 months and all-cause mortality 43%. The HbA1c, and not the OGTT,
was a significant independent predictor for mortality in patients with
DM (Table 3). This study is, probably, the first to describe long-term
mortality in patients with AAA with respect to glycaemic status using
both OGTT and HbA1c values.
4.1. Methodological Considerations
This study was a prospective cohort study of a well-defined

























Hazard ratio for death by Cox regression model
in the DM category by HbA
1c
 results:
Univariate:      HR death 3.19, 95%
[CI 0.80 -12.8]; p 0.10
Multivariate:   HR death 6.35, 95%





















according to OGTT results
Follow-up time (months)
Hazard ratio for death by Cox regression model
in the prediabetes category by OGTT results:
Univariate:      HR death 2.83, 95%
[CI 1.16 -6.89]; p 0.02
Multivariate:   HR death 2.28, 95%
[CI 0.84 - 6.15]; p 0.10
40 60 6040
Fig. 1. Kaplan–Meyer estimation of diabetes related survival curves in patients grouped according to HbA1c resultsc (a) and OGTT resultsd (b). c HbA1c ≥ 6.5% (48 mmol/mol) = diabetes
mellitus, HbA1c range of 5.7–6.4% (39–46 mmol/mol) = prediabetes, and HbA1c b 5.7% (39 mmol/mol) = normoglycaemia. d FPG + 2-h value. DM = FPG ≥ 7.0 mmol/l and/or two-h
value ≥ 11.1 mmol/l. Prediabetes = IGT defined as FPG b 7.0 mmol/L and a 2-h-value between 7.8 mmol/L and 11.1 mmol/L, and IFG defined as fasting glucose value between 6.1 mmol/L
and 7.0 mmol/L with a normal 2-h-value. Normoglycaemia = FPG b 6.1 mmol/L and a 2-h-value b 7.8 mmol/L.
Table 3
Hazard ratio for death according to different glycaemic categories.
Glycaemic categories No. of subjects No. of deaths Crude analysisa Adjusted analysisb
N n (%) HR 95% CI p value HR 95% CI p value
HbA1c results
c
Normoglycaemiad 8 3 (37.5) 1.00 1.00
Prediabetes 42 16 (38.1) 1.00 0.29, 3.44 0.99 0.73 0.21, 2.58 0.62
Diabetes mellitus 8 6(75.0) 3.19 0.80, 12.8 0.10 6.35 1.49, 27.1 0.01
OGTT resultse
Normoglycaemiad 26 7 (26.9) 1.00 1.00
Prediabetes 25 16 (64.0) 2.83 1.16, 6.89 0.02 2.28 0.84, 6.15 0.10
Diabetes mellitus 7 2 (28.6) 1.12 0.23, 5.40 0.87 1.98 0.39, 10.1 0.41
a By cox regression model.
b Adjusted for age, platelet inhibitor and statin.
c HbA1c ≥ 6.5% (48 mmol/mol) = diabetes mellitus, HbA1c range of 5.7–6.4% (39–46 mmol/mol) = prediabetes, and HbA1c b 5.7% (39 mmol/mol) = normoglycaemia.
d Reference category.
e Fasting plasma glucose (FPG) ≥ 7.0 mmol/L and/or two-hour value (2-h-value) ≥ 11.1 mmol/L = diabetes mellitus; IGT (FPG b 7.0 mmol/L and a 2-h-value between 7.8 mmol/L
and 11.1 mmol/L), and IFG (fasting glucose value between 6.1 mmol/L and 7.0 mmol/Lwith a normal 2-h-value) = prediabetes; and FPG b 6.1 mmol/L and a 2-h-value b 7.8 mmol/L =
normal glucose metabolism.
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The follow-up period was up to six years. No patients were lost to
follow-up. The high percentage of male gender, and comorbidities such
as coronary artery disease, hypertension, cerebral arterial disease, in
the study material was comparable to the findings in previous studies
on subjects with AAA (Cornuz, Sidoti, Tevaearai, & Egger, 2004;
Kanagasabay, Gajraj, Pointon, & Scott, 1996; Lederle et al., 1997; Long
et al., 2010). This indicates that the study material was representative
for subjects with AAA, although the sample size was small. All patients
were tested for DMusing both the OGTT and the HbA1c values, hence no
patients were preselected with respect to glycaemic status. The OGTT
and the HbA1c were measured in a standardized way for all patients.
In this study, patients categorized as having DM by OGTT values,
were informed about their DM diagnosis. At the time of inclusion in
the study, HbA1c was not yet implemented as a diagnostic parameter
for the diagnosis of DM, hence patients with HbA1c ≥ 6.5% and OGTT
results below the diagnostic limit of DM, were not informed about the
result. As a consequence, patients with DM by the OGTT criteria may
have received treatment against DM in contrast to patients with
HbA1c ≥ 6.5% and an OGTT result below the diagnostic limit of DM.
This may have influenced the association of mortality with respect to
the OGTT categories. However, a review of the patients' medical
records showed that only one patient with newly diagnosed DM by
the OGTT results received medical treatment for DM at the closure of
the study. Also the mean HbA1c value in patients with DM categorized
by the OGTT results was below 7.0% which is the recommended target
value of HbA1c in the treatment of diabetes. Further the HbA1c criteria
classified three of the seven patients with newly diagnosed DM in
concordance with the OGTT results. The remaining five patients
diagnosed with DM by HbA1c, but not by OGTT results could introduce
a confounding factor as they did not receive information about their
glycaemic status. The results in this study were limited to patients
with AAA, and are not necessarily applicable on general populations
or populations with other vascular pathologies. The statistics in this
study is affected by a small sample size. Therefore it is recommended
that a larger scaled prospective study on patients with AAA should be
performed to confirm these results.
4.2. Clinical Considerations
The results from this study indicate that patients with AAA and DM
diagnosed using HbA1c values have significantly highermortality rates
compared with AAA patients with non-diabetic HbA1c values. This
association was not found in patients with DM by OGTT results when
compared to normal OGTT values. According to the OGTT results
patients with prediabetes showed a significantly higher mortality rate
compared to normoglycaemic patients in a univariate analysis, but
does not follow multivariate adjustment. Due to small sample sizes in
the subgroups of glycaemic categories, the possibility of a type two
error cannot be excluded. However, the mortality rates in relation to
the OGTT results in this study are comparable to the findings of van
Kuijk et al. in patients with peripheral arterial disease (van Kuijk et al.,
2009). De Rango et al found that operative and long-term survival is
lower in patients with AAA and DM compared to patients with AAA
alone, suggesting an increased cardiovascular burden in patients with
AAA and DM (De, Farchioni, Fiorucci, & Lenti, 2014).
Former studies on AAA have, surprisingly, suggested a protective
role of DM against the development of AAA based on the observation
that the prevalence of AAA is lower in diabetic populations compared
with general populations (LaMorte, Scott, & Menzoian, 1995; Lederle
et al., 1997; Mattes et al., 1997; Shah et al., 2014). The studies have not
provided evidence for the pathomechanisms behind these observa-
tions, but glycation of proteins in the media layer of the abdominal
aortic wall and the medical treatment of patients with DM have been
proposed as possible explanations to the lower prevalence of AAA in
diabetic populations (Shantikumar, Ajjan, Porter, & Scott, 2010). The
referred to studies had a preselected study population of patients with
diagnosed DM defined by glucose criteria. Patients with DM who are
unaware of their DM diagnose and patients with DM defined by HbA1c
values are thereby excluded from these studies and may represent a
selection bias. This may lead to a falsely low prevalence of AAA in
patients with DM in these studies. The results from this study on
Norwegian patients with AAA revealed a total prevalence of newly
diagnosed and previously known DM according to the OGTT and the
HbA1c were 23% and 25% respectively. The prevalence of DM in the
general Norwegian population is reported to be 8% at a comparable
category of age (Stene et al., 2004).
4.3. The Role of HbA1c
A large European study on patients with coronary artery disease
(CAD) compared values of FPG, 2-h post glucose load and HbA1c values
when diagnosing DM, and found that in patients with established CAD,
the OGTT defined the largest number of patients with DM. The authors
recommended that the OGTT, and not the HbA1c, should be the
preferred diagnostic test for the diagnosis of DM in patients with CAD
(Gyberg et al., 2015). The study had a cross-sectional design and thus
could not provide information about the impact of the two diagnostic
criteria for diabetes on long-term mortality. The results of this study
indicated that HbA1c, and not the OGTT, was associated with long-term
all-cause mortality in patients with AAA. Patients with AAA have a
high degree of vascular comorbidities, especially CAD and peripheral
occlusive disease (Cornuz et al., 2004; Kanagasabay et al., 1996; Lederle
et al., 1997; Long et al., 2010). An association between glycaemic
control and systemic inflammation in patients with establishedDMhas
been shown both in the diabetic and non-diabetic ranges of HbA1c
(Gustavsson & Agardh, 2004; King, Mainous, Buchanan, & Pearson,
2003; Marques-Vidal et al., 2013). Gustavsson et al. found even an
association of inflammation with HbA1c values in patients with CAD
within the normal range of HbA1c values.
Large epidemiological studies have proven the association of both
OGTTs results and HbA1c values with the development of micro-and
macrovascular disease and mortality (Alssema et al., 2011; Andersson
et al., 2012; McCance et al., 1994; Miyazaki et al., 2004; Selvin et al.,
2004; Skriver, Borch-Johnsen, Lauritzen, & Sandbaek, 2010). Recent
studies on diabetes have shown that the OGTT and the HbA1c criteria
largely define different patients as having DM (Cowie et al., 2010; Doerr
et al., 2011; Hjellestad et al., 2013; Lauritzen et al., 2011; Midthjell &
CMYLCPSC, 2010; Peter et al., 2011; Rathmann et al., 2012). This is in
concordancewithfindings in this study on patientswith AAA. TheOGTT
and the HbA1c represent different metabolic expressions. The OGTT is a
stress-test of the function of pancreatic islet cells whereas HbA1c
represents long term exposure to plasma glucose.
HbA1c may to a greater extent than OGTT express the degree of
macro- and microvascular inflammation. This could be a possible
explanation of the association between HbA1c and all-cause mortality
in this study. This study was, however, not designed to give an answer
to this assumption.
4.4. Prediabetes
According to the American College of Cardiology/American Heart
Association guidelines for the treatment of peripheral vascular disease,
DM is recognized as an atherosclerotic risk factor (Anonymous, 2003).
Notable is the observation of the high prevalence of prediabetes
according to HbA1c values in this study (Table 2). Results show a trend
toward higher mortality in patients with prediabetes compared
with patients with normal HbA1c values. The results were, however,
not statistically significant. The results may indicate that patients
with AAA and prediabetes according toHbA1c values should be included
in a postoperative outpatient program to prevent and monitor the
development of DM.
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5. Conclusion
DM defined by HbA1c ≥ 6.5% is an important determinant of
mortality following surgical treatment for AAA. Patients with AAA
have high prevalence of DM and high all-cause mortality. Half the
patients with AAA and DM are unaware of their DM diagnosis. Patients
with DM as defined by HbA1c values have a significantly higher
mortality compared to normoglycaemic AAApatients. The results of this
study indicate that all patients with AAA should be tested for DM by
using the HbA1c, and the results may have implications on medical
treatment of patients with AAA. The results should, however, be
confirmed in a larger prospective study and, if verified, followed by a
prospective intervention study targeting glucose control.
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Highlights
• Mortality during a 9-year follow-up of patients with peripheral arterial disease
was 40%.
• HbA1c is a useful marker in preoperative risk assessment of patients with
unknown glycemic status at admission for vascular surgery.
Abstract
Background: Peripheral arterial disease (PAD) and diabetes mellitus
(DM) represent major public health challenges and are tightly associated. To facili-
tate early diagnosis, HbA1c has been implemented as the preferred diagnostic tool
for the diagnosis of type 2 DM. In this study, we compared and evaluated HbA1c,
fasting plasma glucose (FPG), and 2-hour post-load glucose values to determine
which test best predicted mortality in patients with PAD.
Methods: In all, 273 PAD patients with unknown glycemic status admitted to Hau-
keland University Hospital for elective surgery between October 2006 and
September 2007 were included in the study. All 273 patients underwent a standard
oral glucose tolerance test (OGTT) in addition to determination of HbA1c; patients
were then grouped into those with DM, intermediate hyperglycemia, and normo-
glycemia according to World Health Organization and International Expert Com-
mittee criteria.
Results: All-cause mortality was 40% over a 9-year follow-up period. After adjust-
ing for age, sex, and relevant medication, HbA1c was a predictor for mortality
(hazard ratio [HR] 1.54; 95% confidence interval [CI] 1.03-2.32]; P = 0.04). The
association did not achieve statistical significance in a fully adjusted Cox regres-
sion model, although the effect estimation of HbA1c on all-cause mortality
remained largely unchanged (HR 1.39; 95% CI 0.92-2.09; P = 0.13). The OGTT
was not a predictor of long-term mortality.
Conclusions: The results indicate that HbA1c is a useful marker in the preopera-
tive screening of patients of unknown glycemic status at the time of admission for
vascular surgery, and may identify people at high risk of long-term mortality fol-
lowing surgical treatment for PAD.
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1 | INTRODUCTION
Peripheral arterial disease (PAD) and diabetes mellitus
(DM) are tightly associated.1 Based on fasting plasma glu-
cose (FPG) levels, an oral glucose tolerance test (OGTT), or
a self-reported DM diagnosis, patients with PAD are
reported to have a higher prevalence of DM compared with
general populations and populations at risk of developing
DM.2–6 In Norwegian vascular surgery patients, a 55% prev-
alence of hyperglycemia and a DM frequency of 29% were
found as defined by FPG and an OGTT.7
The diagnostic criteria for DM have changed over time
along with the development and improvement in biochemi-
cal tests. The diagnosis of diabetes is currently based on
either an FPG ≥7.0 mmol/L, a 2-hour post-load glucose
(2hPG) ≥11.1 mmol/L, or HbA1c ≥48 mmol/mol
(6.5%).8–10
Studies have shown that FPG, 2hPG, and HbA1c levels
primarily define different groups of patients as having
DM.4,11–13 In addition, patients with PAD and DM, defined
by FPG or an OGTT, have higher mortality than patients
with PAD alone.1,14,15
It is of major importance to investigate the consequences
of unknown DM in PAD patients when using the current
three diagnostic criteria for the DM diagnosis. The aim of
the present study was to compare HbA1c, FPG and 2hPG
values and to evaluate which test best predicts long-term
mortality in patients with PAD.
2 | METHODS
This study is a prospective cohort study of patients with
unknown glycemic status at the time of admission for vascu-
lar surgery.
2.1 | Study population
Initially, 465 patients admitted to Haukeland University
Hospital for elective surgery between October 2006 and
September 2007 were invited to participate in the study
(Figure 1). Twenty-one patients died before deciding
whether to participate, 66 declined to undergo an OGTT,
and 33 did not have an OGTT performed due to logistic rea-
sons. Furthermore, a DM diagnosis had been previously
established in 67 patients. Thus, complete data on HbA1c,
FPG, and 2hPG values from 273 vascular surgery patients
were included for statistical analyses in the present study
with unknown glycemic status (Figure 1). The vascular
pathologies were carotid stenosis, abdominal aortic aneu-
rysm (AAA), iliac occlusive disease (IOD) including lesions
in the common femoral artery, and infrainguinal occlusive
disease. Informed written consent was obtained from all par-
ticipants. The research protocol was approved by the
Norwegian Regional Committee for Medical and Health
Research Ethics (REK vest 14109).
2.2 | Inclusion and exclusion criteria
All patients admitted for elective vascular surgery due to athero-
sclerotic disease and competent to give consent to participate in
the study were considered eligible for inclusion. Patients admit-
ted for emergency procedures, patients with non-atherosclerotic
conditions, patients with dementia or mental disability, and
patients with known DM were excluded from the study.
2.3 | Diagnostic tests
Throughout this paper, the term “OGTT” refers to the measure-
ments of both FPG and 2hPG, unless stated otherwise. The
OGTT was performed according to World Health Organization
(WHO) guidelines.8 Plasma glucose concentrations were mea-
sured in a fasting state and again 2 hours after the administration
of a 75-g glucose load. Diet recommendations were not given
prior to the OGTT and HbA1c measurements. Plasma glucose
concentrations were primarily assayed using Modular P analyti-
cal system (Roche Diagnostics). The HbA1c values were mea-
sured in samples of venous whole blood and analyzed using a
Variant II HPLC system (Bio-Rad). The diagnostic tests have
been described in detail elsewhere.16
The OGTT results were categorized according to 2006
WHO criteria,8 whereas HbA1c results were categorized
FIGURE 1 Flow-chart showing the selection of study participants
admitted to Haukeland University Hospital, Norway, for elective vascular
surgery between October 2006 and September 2007. DM, diabetes mellitus;
OGTT, oral glucose tolerance test
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according to the 2011 WHO statement10 and the Interna-
tional Expert Committee statement of 2009.17 Diabetes was
defined as FPG ≥7.0 mmol/L, 2hPG ≥11.1 mmol/L, or
HbA1c ≥48 mmol/mol (6.5%). Patients at high risk of devel-
oping DM were defined as those with HbA1c in the range
42 to 46 mmol/mol (6.0%-6.4%), FPG between 6.1 and
7.0 mmol/L, and 2hPG between 7.8 and 11.1 mmol/L.
2.4 | Other variables
Baseline data on age, sex, smoking habits, vascular bed
affected, cholesterol levels, medication, and comorbidities
were obtained from patients' medical records. The Modifica-
tion of Diet in Renal Disease equation was used to calculate
the estimated glomerular filtration rate (eGFR).18 Reduced
renal function was defined as eGFR <60 mL/min per
1.73 m2.
2.5 | Endpoints and follow-up
Study participants were followed from the date of surgical
intervention either to the date of death or to the date of study
closure on 30 August 2016. Data on all-cause mortality were
obtained from the Norwegian civil registry. Death of any
cause was used as the primary endpoint. An autopsy was
performed only on one-third of patients who died during the
follow-up period; hence, causes of death were not recorded
in the present study.
2.6 | Statistical analysis
Data were analyzed using IBM (Armonk, New York) SPSS
Statistics 24 and R version 3.4.0 for Windows
(R Foundation for Statistical Computing, Vienna, Austria).
Data are presented as the mean  SD for continuous
variables and as counts with percentages for categorical vari-
ables. The significance of differences in patient baseline
characteristics for patients alive at end study and patients
who died during follow-up was explored using χ2 tests for
categorical data and independent samples t tests for
continuous data.
Cox regression models were used to estimate all-cause
mortality hazard ratio (HR) with 95% confidence intervals
(CIs) for HbA1c, FPG, and 2hPG values at baseline. Multi-
variate Cox regression analysis was performed using
HbA1c, FPG, and 2hPG values as continuous variables. A
Firth regression model was used to estimate all-cause mortal-
ity HRs according to different vascular pathologies and gly-
cemic categories based on both HbA1c and OGTT results.
Event-free time was the time from study inclusion until
death or censoring. All patients were monitored from enrol-
ment until death or until 30 August 2016. Based on the
selection of appropriate covariates according to known risk
factors associated with DM and PAD, three models were
constructed to evaluate the effect of possible confounding.
Model 1 was adjusted for age and sex. Model 2 was adjusted
for age, sex, and the use of platelet inhibitors, statins, and
antihypertensive medication. Model 3 was a fully adjusted
model that included low-density lipoprotein cholesterol,
smoking status, a history of coronary artery disease (CAD),
a history of cerebrovascular disease and a history of reduced
renal function in addition to the covariates included in
Models 1 and 2. Model fit was examined by a global test of
the proportional hazards assumption. Complete-case ana-
lyses were used for all survival models. The variance infla-
tion factor was used to test for multicollinearity.
Kaplan–Meier curves were used to illustrate survival
with time according to glycemic status based on OGTT
results (FPG and 2hPG values) and HbA1c values. The log-
rank test was used to test for differences in survival across
glycemic categories.
A power calculation was not performed prior to the
recruitment of patients to the study and this study should
therefore be considered exploratory. However, the number
of events per variable was within an acceptable level.
3 | RESULTS
3.1 | Glycemic status
Baseline characteristics of the study population based on
glycemic status are presented in Table 1. The prevalence of
newly diagnosed DM was 12% based on OGTT results and
15% based on HbA1c levels (Figure 2; Supporting Informa-
tion Table S1). The HbA1c values and OGTT results largely
classified different patients as having newly diagnosed
DM. Twenty-five of 40 patients (63%) with HbA1c ≥6.5%
had a non-DM OGTT result. In addition, 22% of patients
categorized with prediabetes based on OGTT results had an
HbA1c ≥6.5%.
3.2 | Mortality
All-cause mortality was 40% (n = 110) among the 273 vas-
cular surgery patients with unknown glucose status at base-
line, and higher for patients with AAA (55%) and
infrainguinal occlusive disease (45%) than for those with
carotid stenosis (24%) and IOD (15%); (Supporting Informa-
tion Table S2). Mortality in patients with known DM at
baseline (n = 67) was 79%. Patients who died during
follow-up had significantly higher mean HbA1c at baseline
than patients who were alive at the end of the study. Patients
who died during follow-up were also older, had a higher
prevalence of reduced renal function, and more often had a
history of CAD (Table 2). Patients who were alive at the end
of the study were more often treated with antiplatelet therapy
than those who died during follow-up. The mean follow-up
time was 2805 days and the median follow-up time was
3296 days (range 0-3779 days). Independent variables for
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TABLE 1 Baseline characteristics of study participants (n = 273) by glycemic status (follow-up ended on 30 August 2016 = 7.8 years)
HbA1c (%) OGTTb
Characteristics Reference populationa 6.0-6.4 ≥6.5 PreDMc DMd
No. participants 70 (26) 122 (45) 40 (15) 90 (34) 33 (12)
Age (years)
Mean 67.6 70.3 71.6 71.5* 71.1
Range 49-87 35-88 54-89 48-89 59-88
Sex
Female 21 (30) 38 (31) 8 (20) 15 (17) 8 (24)
Male 49 (70) 84 (69) 32 (80) 75 (83) 25 (76)
BMI (kg/m2)
Mean  SD 25.2  4.3 25.2  4.4 27.7  4.4* 26.4  4.4 27.0  3.3
Range 16.7-35.8 16.4-38.9 18.5-36.1 17.7-38.9 22.2-32.9
No. of cases with missing data 36 55 13 37 12
Vascular pathology
Carotid stenosis 11 (16) 17 (14) 8 (20) 10 (11) 6 (18)
AAA 16 (23) 25 (21) 8 (20) 25 (28) 7 (21)
IOD 18 (26) 22 (18) 2 (5) 6 (7) 3 (9)
InOD 23 (33) 57 (47) 21 (53)* 48 (53)* 16 (49)
Peripheral arterial aneurysms 2 (3) 1 (1) 1 (3) 1 (1) 1 (3)
Smoking status
Non-smoker 8 (11) 24 (20) 6 (15) 10 (11) 9 (27)
Former or current smoker 57 (81) 94 (77) 33 (83) 77 (86) 21 (64)
No. of cases with missing data 3 (7) 4 (3) 1 (3) 3 (3) 3 (9)
Renal functione
Normal 60 (86) 87 (71) 25 (63) 56 (62) 24 (73)
Reduced 10 (14) 34 (28)* 13 (33)* 32 (36)* 9 (27)
No. of cases with missing data 0 1 (1) 2 (5) 2 0
Medical history
Antihypertensive treatment
No 21 (30) 26 (21) 4 (10) 14 (16) 6 (18)
Yes 49 (70) 96 (79) 36 (90)* 76 (84) 27 (82)
CVD
No 55 (79) 99 (81) 28 (70) 71 (79) 23 (70)
Yes 15 (21) 23 (19) 12 (30) 19 (21) 10 (30)
CAD
No 52 (74) 66 (54) 16 (40) 48 (53) 19 (58)
Yes 18 (26) 56 (46)* 24 (60)** 42 (47)* 14 (42)
Medical treatment
Statins
No 9 (13) 16 (13) 2 (5) 13 (14) 0
Yes 61 (87) 106 (87) 38 (95) 77 (86) 33 (100)
Antiplatelet agents
No 6 (9) 20 (16) 7 (18) 17 (19) 1 (3)
Yes 64 (91) 102 (84) 33 (83) 73 (81) 32 (97)
FPG (mmol/L)
Mean  SD 5.2  0.5 5.5  0.6* 6.6  1.3** 5.9  0.5** 7.1  1.4**
Range 4.1-6.0 4.2-7.3 4.8-9.8 4.4-6.7 5.2-10.5
2hPG (mmol/L)
Mean  SD 5.4  1.2 7.0  3.4** 10.2  3.5** 8.3  1.9** 13.2  4.7**
Range 2.4-7.6 2.9-31.8 3.8-18.8 2.3-10.9 3.0-31.8
No. of cases with missing data 0 0 2 0 2
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TABLE 1 (Continued)
HbA1c (%) OGTTb
Characteristics Reference populationa 6.0-6.4 ≥6.5 PreDMc DMd
HbA1c (%)
Mean  SD 5.7  0.2 6.2  0.1** 6.8  0.5** 6.1  0.4** 6.5  0.7**
Range 5.1-5.9 6.0-6.4 6.5-8.8 5.0-7.2 5.2-8.8
Total cholesterol (mmol/L)
Mean  SD 4.6  1.0 4.6  1.1 4.3  1.0 4.5  1.1 4.4  1.0
Range 2.5-6.9 2.5-7.7 2.3-6.7 2.0-9.1 2.3-6.8
No. of cases with missing data 1 0 0 0 0
LDL-C (mmol/L)
Mean  SD 2.8  0.9 2.8  1.0 2.5  0.9 2.7  1.1 2.7  0.9
Range 1.1-5.1 0.9-5.5 1.0-4.7 0.9-7.4 1.1-5.0
No. of cases with missing data 2 1 0 0 0
Abbreviations: AAA, abdominal aortic aneurysm; BMI, body mass index; CAD, coronary artery disease; CVD, cardiovascular disease; InOD, infrainguinal occlusive
disease; IOD, iliac occlusive disease; LDL-C, low-density lipoprotein cholesterol.
Unless indicated otherwise, data are given as n (%).
*P < 0.05,; **P < 0.001 compared with the reference population. The P-values given in the table refer to the association between patients grouped in different glyce-
mic categories compared with the reference population and were determined using the Chi-squared test for categorical variables and ANOVA for continuous variables.
aThe reference population consisted of participants with normal HbA1c, fasting plasma glucose (FPG) and 2-hour post-load glucose (2hPG) values.
bThe oral glucose tolerance test categories are based on both FPG and 2hPG values.
cPrediabetes (PreDM) was defined as FPG <7.0 mmol/L and 2hPG between 7.8 and 11.1 mmol/L, and/or FPG between 6.1 and 7.0 mmol/L with a normal 2hPG.
dDiabetes mellitus (DM) was defined as FPG ≥7.0 mmol/L and/or 2hPG ≥11.1 mmol/L.
eRenal function was classified as normal if the estimated glomerular filtration rate (eGFR) was >60 mL/min per 1.73 m2 and as reduced if eGFR was <60 mL/min per
1.73 m2.
TABLE 2 Baseline characteristics according to alive/dead status at the end of the follow-up period
Characteristics All patients Died during follow-up Alive at end of study P-value
Total (%) 273 (100) 110 (40) 163 (60)
Age (years)
Mean 69.6 74.1 66.5 <0.0001a
Range 35-89 53-89 35-87
Sex 0.07b
Female 73 (26.7) 23 (21) 50 (31)
Male 200 (73.3) 87 (79) 113 (69)
BMI (kg/m2)
Mean  SD 25.7  4.3 24.9  4.6 26.2  4.0 0.05a
Range 16.4-38.9 16.4-36.1 18.5-38.9
No. of cases with missing data 112 (41) 46 (42) 66 (40)
Vascular pathology
Carotid stenosis 42 (100) 10 (24) 32 (76)
AAA 60 (100) 33 (55) 27 (45)
IOD 47 (100) 7 (15) 40 (85)
InOD 119 (100) 58 (49) 61 (51)
Peripheral arterial aneurysms 5 (2) 2 (40) 3 (60)
Smoking status NSa
Non-smoker 42 (15.5) 20 (18) 22 (14)
Former or current smoker 219 (80) 87 (79) 132 (81)
No. of cases with missing data 12 (4.5) 3 (3) 9 (6)
Renal functionc 0.007b
Normal 199 (73) 71 (65) 127 (78)
Reduced 71 (26) 39 (36) 33 (20)
No. of cases with missing data 3 0 3 (2)
Medical history
CVD NSb
No 212 (78) 84 (76) 131 (80)
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mortality were age, male sex, and lack of treatment with
platelet inhibitors.
Differences in survival between glycemic categories are
shown in Figure 3. Patients diagnosed with DM according to
HbA1c values had significantly higher mortality during
follow-up than patients with normal HbA1c (P = 0.015).
Patients diagnosed with intermediate hyperglycemia based
on OGTT results, but not fulfilling the criteria for DM, had
significantly higher mortality than normoglycemic patients
(P = 0.001).
In crude analysis, as well as in the age- and sex-adjusted
Cox regression model (Model 1), HbA1c was significantly
associated with all-cause mortality (P = 0.01; Table 3). The
association remained statistically significant after adjusting
for age, sex, and the use of platelet inhibitors, statins, and
antihypertensive medication (P = 0.04; Model 2, Table 3).
In a fully adjusted Cox regression model, the effect size of
HbA1c on all-cause mortality remained largely unchanged,
but the association was no longer significant (P = 0.13;
Model 3, Table 3). Fasting plasma glucose and 2hPG values
TABLE 2 (Continued)
Characteristics All patients Died during follow-up Alive at end of study P-value
Yes 61 (22) 26 (24) 32 (20)
No. of cases with missing data 0 0 0
CAD <0.0001b
No 180 (66) 50 (46) 113 (69)
Yes 93 (34) 60 (55) 50 (31)
No. of cases with missing data 0 0 0
Medical treatment
Antihypertensives 0.03b
No 142 (52) 17 (16) 43 (26)
Yes 131 (48) 93 (85) 120 (74)
No. of cases with missing data 0 0 0
Statins 0.05b
No 30 (11) 17 (16) 13 (8)
Yes 243 (89) 93 (85) 150 (92)
Antiplatelet agents <0.0001b
No 37 (14) 28 (26) 9 (6)
Yes 236 (86) 82 (75) 154 (95)
FPG (mmol/L)
Mean  SD 5.7  0.9 5.8  1.1 5.6  0.7 NSa
Range 4.1-10.5 4.2-10.5 4.1-9.4
2hPG (mmol/L)
Mean  SD 7.3  3.3 7.8  3.7 7.0  2.9 0.04a
Range 2.3-31.8 2.3-31.8 2.4-18.3
HbA1c (%)
Mean  SD 6.1  0.5 6.2  0.5 6.0  0.4 0.003a
Range 5.0-8.8 5.1-8.8 5.0-7.9
Total cholesterol (mmol/L)
Mean  SD 4.5  1.1 4.4  1.0 4.6  1.1 NSa
Range 2.0-9.1 2.0-7.5 2.5-9.1
No. of cases with missing data 1 (0.4) 0 1 (0.6)
LDL-C (mmol/L)
Mean  SD 2.8  1.0 2.7  1.0 2.8  1.1 NSa
Range 0.9-7.4 0.9-5.1 1.0-7.4
No. of cases with missing data 3 (1.1) 0 3 (2)
Abbreviations: 2hPG, 2-hour post-load glucose; AAA, abdominal aortic aneurysm; BMI, body mass index; CAD, coronary artery disease; CVD, cardiovascular disease;
FPG, fasting plasma glucose; InOD, infrainguinal occlusive disease; IOD, iliac occlusive disease; LDL-C, low-density lipoprotein cholesterol.
Note, percentages in the table may not add up to 100 due to rounding.
Unless indicated otherwise, data are given as n (%). The P-values given in the table refer comparisons between patients who died during follow-up and those who were
alive at the end of the study.
a Independent samples t test.
b Chi-squared test.
c Renal function was classified as normal if the estimated glomerular filtration rate (eGFR) was >60 mL/min/1.73 m2 and as reduced if eGFR was <60 mL/min/
1.73 m2.
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were not independent predictors for mortality in any of the
three models (Table 3). The proportional hazards assumption
was fulfilled for all variables. No variables were found to be
highly correlated. The number of events per variable was
110/10 = 11.
Additional analyses of HRs for death according glycemic
categories in the different vascular pathologies were per-
formed (Supporting Information Table S3). Results from a
fully adjusted Firth regression model were not available for
patients with IOD due to a small number of events combined
with a high number of adjustment variables.
3.3 | Medical treatment
At the time of inclusion, 243 of 273 patients (89%) were
receiving statins, 236 (86%) were receiving antiplatelet
FIGURE 2 Venn diagram showing the prevalence of newly diagnosed A, diabetes mellitus (DM) and B, intermediate hyperglycemia based on HbA1c
results (blue circles) and results of the oral glucose tolerance test (OGTT). The two methods largely classified different patients as having newly diagnosed
DM and intermediate hyperglycemia: the prevalence of newly diagnosed DM was 12% based on OGTT results and 15% based on HbA1c levels. Twenty-five
of 40 patients (63%) with HbA1c ≥6.5% had a non-DM OGTT result
FIGURE 3 Crude survival curves for vascular surgery patients grouped according to A, HbA1c results and B, results of the oral glucose tolerance test
(OGTT). Using HbA1c levels, values ≥6.5% (48 mmol/mol) were considered indicative of diabetes mellitus (DM), whereas HbA1c in the range 6.0% to 6.4%
(43-46 mmol/mol) was considered intermediate hyperglycemia and HbA1c <6.0% (43 mmol/mol) was considered to indicate normoglycemia. Based on
fasting plasma glucose (FPG) values and 2-hour post-glucose load values (2hPG), OGTT results were categorized as follows: DM was defined as FPG ≥ 7.0
mmol/l and/or 2hPG ≥ 11.1 mmol/l; intermediate hyperglycaemia was defined as impaired glucose tolerance (FPG < 7.0 mmol/L and a 2-hour post glucose
load value between 7.8 mmol/L and 11.1 mmol/L) and/or impaired fasting glucose (FPG between 6.1 mmol/L and 7.0 mmol/L with a normal 2hPG); and
normoglycaemia was defined as FPG <6.1 mmol/L and 2hPG <7.8 mmol/L. CI, confidence interval
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therapy, 22 (8%) were receiving warfarin, and 213 (78%)
were receiving antihypertensive treatment. Fifty-four (25%)
of the 213 patients who received antihypertensive treatment
were being treated with three or more antihypertensives.
Nine of the 33 (27%) patients with newly diagnosed DM
based on OGTT results received antidiabetic therapy at the
end of the study and 13 (39%) died during follow-up. Of the
13 patients who died during follow-up, two patients received
medical treatment for DM and 11 did not use antidiabetic
medication at study closure.
4 | DISCUSSION
The findings of this study indicate that HbA1c is a useful
marker in the preoperative screening of patients of unknown
glycemic status admitted for vascular surgery. The results of
HbA1c testing may identify people at high risk of long-term
mortality following surgical treatment for PAD. Thus,
HbA1c results may be of importance for preoperative risk
assessment in this group of patients.
To the best of our knowledge, the present study is the
only long-term follow-up study to have evaluated HbA1c
and OGTT as predictors of mortality in patients with PAD.
Five year all-cause mortality in patients with PAD has
been reported to be in the range 19% to 37%,19–21 and
10-year all-cause mortality has been reported to range from
42% to 54%.20,22 In accordance with these studies, the total
mortality in the present study, when including patients with
known DM, was 48%. Research has shown that approxi-
mately one-third of patients with type 2 DM are unaware of
their DM diagnosis, and are hence untreated and at high risk
of developing vascular complications.23 Similarly, one-third
of patients with PAD and DM in the present study were
unaware of their DM diagnosis.
Several previous studies have aimed to compare mortal-
ity in patients with PAD and with or without established
DM. Those studies concluded that individuals with PAD and
DM had significantly higher mortality than individuals with
PAD only.1,24–26 In those studies, patients with known DM
had been diagnosed using FPG and/or 2hPG values. The
studies did not provide information about mortality in
patients with newly diagnosed DM. Due to variations in the
definition of glycemic status, variations in the vascular
pathology studied, and variations in the groups of patients
selected for comparison, it is difficult to interpret results
from studies investigating mortality and glycemic status in
patients with vascular disease. In the present study, patients
with established PAD and unknown glycemic status were
tested for DM using both HbA1c and OGTT criteria. When
categorizing patients as DM, intermediate hyperglycemia, or
normoglycemia, patients with newly diagnosed DM based
on HbA1c values had significantly higher mortality in crude
analysis than patients with normal HbA1c. Results from the
OGTTs showed that patients with intermediate hyperglyce-
mia, but not patients with DM, had significantly higher mor-
tality in crude analysis than patients with normal OGTT, as
also reported by van Kuijk et al25 The present study was not
designed to explore causality for the association of glycemic
status with all-cause mortality. However, several possible
explanations may be discussed. Patients with intermediate
hyperglycemia based on OGTT results were more likely to
be former or current smokers than DM patients. This may
have affected the association of OGTT status with all-cause
mortality.
Another possible explanation could be the discordance
in classification into glycemic categories when using OGTT
results compared with HbA1c results. Twenty (22%) of the
patients with intermediate hyperglycemia based on OGTT
results were categorized as having DM according to HbA1c
results.
Patients with DM according to HbA1c and patients with
prediabetes based on OGTT results shared some baseline
features, which may explain, in part, the similarities in mor-
tality between the two groups. Patients in both categories
were significantly older and were more likely to have
reduced renal function, a medical history of CAD, and infra-
inguinal occlusive disease at baseline than participants with
normal HbA1c, FPG, and 2hPG values (reference
population).
Further, patients with DM based on OGTT results were
informed about their DM diagnosis. However, at the time of
inclusion in the study, HbA1c was not yet implemented as a
diagnostic criterion for DM. Hence, patients with HbA1c
≥6.5% and a non-DM OGTT result were not informed of
TABLE 3 Hazard ratios for death during follow-up according to HbA1c, fasting plasma glucose and 2-hour post-load glucose values
HbA1c FPG 2hPG
HR (95% CI) P-value HR (95% CI) P-value HR (95% CI) P-value
Crude 1.75 (1.24-2.46) 0.01 1.13 (0.93-1.38) 0.21 1.07 (1.01-1.12) 0.01
Model 1 1.67 (1.15-2.44) 0.01 1.12 (0.90-1.40) 0.31 1.03 (0.96-1.09) 0.43
Model 2 1.54 (1.03-2.32) 0.04 1.12 (0.89-1.41) 0.35 1.03 (0.97-1.10) 0.35
Model 3 1.39 (0.92-2.09) 0.13 1.10 (0.87-1.39) 0.44 1.03 (0.96-1.10) 0.42
Abbreviations: CI, confidence interval; FPG, fasting plasma glucose; HR, hazard ratio.
Model 1 was adjusted for age and sex.
Model 2 was adjusted for age, sex, and the use of platelet inhibitors, statins, and antihypertensive medication.
Model 3 was the fully adjusted model, adjusted for low-density lipoprotein cholesterol, smoking status, history of coronary artery disease, history of cerebrovascular dis-
ease and history of reduced renal function in addition to the covariates included in Models 1 and 2.
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their results. Consequently, treatment for newly diagnosed
DM may vary between these groups, which may represent a
confounding factor in this study. Conversely, only nine
patients (27%) with newly diagnosed DM based on OGTT
results, of whom five also had DM according to HbA1c
values, received medical treatment for DM at the end of the
study, reducing the difference in treatment between the
groups. Mean HbA1c values in patients with DM catego-
rized based on OGTT results was 6.5%, which is below the
recommended target value of HbA1c in the treatment of
DM. This may be a possible explanation for the low treat-
ment rate of newly diagnosed DM in this study population.
It has been reported that HbA1c and the OGTT largely
define different groups of patients as having DM.11–13,23 This
is in accordance with previous published results from the pre-
sent study population.16 Oral glucose tolerance test and
HbA1c values represent different metabolic expressions. The
OGTT is a stress test of pancreatic islet cell functioning,
whereas HbA1c represents long-term exposure to plasma glu-
cose. Sustained hyperglycemia may induce non-enzymatic
glycation of lipoproteins and thereby start a cascade of
changes in the endothelial cells that may lead to endothelial
dysfunction.27 Thus, HbA1c may, to a greater extent than
OGTT results, express the degree of macro- and microvascu-
lar inflammation. This could possibly explain the association
between HbA1c and all-cause mortality in the present study.
However, the present study was not designed to provide an
answer to this assumption. Further studies on the association
between HbA1c and inflammation are needed to explore
whether this association could be a possible target in future
research regarding treatment of patients with PAD and DM.
Studies have shown that both OGTT (FPG and 2hPG)
and HbA1c levels are associated with future risk of develop-
ing DM.11,28 Of note is the high number of patients catego-
rized as having prediabetes according to HbA1c results in
the present study (Figure 2). This study does not provide
data on the development from prediabetes into DM during
the follow-up period. However, one could speculate that a
higher number of patients in the prediabetes group based on
HbA1c results may develop DM during the follow-up period
than in the prediabetes group based on OGTT results. If so,
this would support the conclusion on the association
between HbA1c and long-term mortality in the present
study. In contrast, recent research has shown that the conver-
sion rate from prediabetes to DM in patients with prediabetes
is higher based on OGTT than HbA1c results.29 Hence, we
cannot exclude the possibility that the association between
OGTT results and mortality in the present study may be
underestimated.
In the present study, HbA1c was a predictor for all-cause
mortality in crude analysis, as well as after adjustment for
age, sex, and medical treatment. The association of HbA1c
with all-cause mortality did not achieve statistical signifi-
cance in multivariate analysis, although the effect estimation
of HbA1c on all-cause mortality remained primarily
unchanged. This could be explained by a lack of statistical
power due to sample size, and by the possibility of multicol-
linearity. Hence, this study should be considered an explor-
atory study. The results from subanalyses of HRs for death
according to glycemic categories in patients with different
vascular pathologies indicate that the association of HbA1c
with all-cause mortality remained significant for patients
with carotid stenosis and AAA. No statistically significant
association of HRs for death with different glycemic catego-
ries was seen for patients with peripheral occlusive disease,
although the effect estimation was 1.45 in Model 2. How-
ever, the results are affected by a low statistical power in this
subanalysis. A larger study is needed to enable solid conclu-
sions to be reached for each of the vascular pathologies.
O'Sullivan et al30 investigated 30-day morbidity and
mortality, as well as 6-month mortality, in 122 PAD patients
without DM and found a significant association between
HbA1c and 30-day morbidity. In contrast with the findings
of the present study, O'Sullivan et al30 did not find an associ-
ation of HbA1c with mortality. Fifty-eight percent of
patients without DM had HbA1c values of 6.0% to 6.9%,
and nine patients died during a follow-up period of
6 months.30 The results of O'Sullivan et al30 were affected
by a small sample size, a short follow-up time, and selection
bias regarding glycemic status.
In accordance with the results of the present study, data
on general populations in both Western countries and Asian
populations have demonstrated a positive association of
HbA1c levels with morbidity and mortality of cardiovascular
disease in people without DM.31–33
Due to an established outpatient program at the Depart-
ment of Vascular Surgery, Haukeland University Hospital, no
patients were lost during follow-up. However, the fact that
66 patients declined to participate in the study and a further
21 patients died before deciding to participate may have intro-
duced a selection bias. Of the 66 who declined to take part in
the study, 50% were male. Therefore, a selection bias regard-
ing sex cannot be excluded. However, mean FPG values and
the prevalence of newly diagnosed DM based on FPG values
alone were the same in the 66 patients as in the study partici-
pants. The 21 patients who died had high morbidity and were
older than the study population, and are therefore not neces-
sarily comparable to the participants in the present study.
Thus, selection bias is believed to have had only a minor
effect on overall conclusions, although it cannot be excluded.
Finally, an autopsy was only performed on one-third of
patients who died during the follow-up period. Hence, only
all-cause mortality was recorded in the present study.
5 | CONCLUSION
The present exploratory study suggests that HbA1c is a use-
ful marker in the preoperative screening of PAD patients
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with unknown glycemic status at the time of admission for
vascular surgery. The HbA1c results may identify people at
high risk of long-term mortality following surgical treatment
for PAD. Clinicians should consider including HbA1c for
preoperative risk assessment in PAD patients.
A large-scale study should be performed to confirm the
results reported herein and to evaluate whether the conclu-
sion holds for different vascular pathologies. Further, an
intervention study targeting glucose control should be con-
sidered to explore possible implications on mortality and
relapse of the vascular pathology.
In addition, the possible association of HbA1c with hyperin-
sulinemia and inflammatory markers in patients with PAD
should be investigated as a potential target in the treatment of
patients with PAD and abnormal glucose metabolism.
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Supplementary tables. Diabetes and mortality in PAD. 
  1 
 
 
a HbA1c ≥ 6.5% (48 mmol/mol) = diabetes mellitus, HbA1c range of 6.0-6.4% (42-46 mmol/mol) = prediabetes, 
and HbA1c < 6.0%  (< 42 mmol/mol) = normal HbA1c. 
b FPG+2-h post glucose load value. 
 
 
Supplementary Table 2. Mortality according to affected vascular bed. 
Vascular pathology  Alive at end study 
n (%) 
Dead during follow-up 
n (%) 
 Total 
      
Carotid stenosis  32 (76) 10 (24)  42 (15) 
AAA*  27 (45) 33 (55)  60 (22) 
IOD**  40 (85) 7 (15)  47 (17) 












Total  163 (60) 110 (40)  273 (100) 
* AAA=abdominal aortic aneurysm 






Supplementary Table 1. The number of patients categorized as having normoglycaemia, 
prediabetes and diabetes mellitus according to HbA1ca versus OGTTb results. 
   HbA1ca 
OGTTb Subjects  
Normo- 
glycaemia 
(%)  Prediabetes (%)  
Diabetes 
mellitus (%) 
        
Total 273  111 (40.7)  122 (44.7)  40 (14.7) 
        
Normoglycaemia 150  70 (46.7)  75 (50.0)  5 (3.3) 
Prediabetes 90  34 (37.8)  36 (40.0)  20 (22.2) 
Diabetes mellitus  33    7 (21.2)  11 (33.3)  15 (45.5) 
        
Supplementary tables. Diabetes and mortality in PAD. 
  2 
 
 
Supplementary Table 3. HR for death in glycaemic categories and according to affected 
vascular bed. 































            
Model 1a            
Overalld 1.67 1.15-2.44 0.01  1.12 0.90-1.40 0.31  1.03 0.96-1.09 0.43 





















AAAe 2.17 0.99-4.34 0.05  1.21 0.80-1.24 0.24  1.08 0.96-1.21 0.18 





















            
Model 2b            
Overalld 1.54 1.03-2.32 0.04  1.12 0.89-1.41 0.35  1.03 0.97-1.10 0.35 





















AAAe 2.53 1.05-5.44 0.04  1.20 0.79-1.73 0.37  1.08 0.94-1.23 0.27 





















            
Model 3c            
Overalld 1.39 0.92-2.09 0.13  1.10 0.87-1.39 0.44  1.03 0.96-1.10 0.42 
            
Carotid 
stenosise 
69.2 2.7-14675 0.01  1.39 0.52-3.14 0.48  1.11 0.80-1.40 0.46 
AAAe 2.93 1.08-7.02 0.04  1.07 0.69-1.57 0.74  1.09 0.94-1.24 0.24 





















            
a Adjusted for age and sex.  
b Adjusted for age, sex, and the use of platelet inhibitors, statins and antihypertensive medication.  
c Fully adjusted model. Adjusted for low-density lipoprotein cholesterol, smoking status, history of coronary 
artery disease, history of cerebrovascular disease and history of reduced renal function in addition to covariates 
included in Models 1 and 2. 
d estimation by Cox regression model.  
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